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Abstract 
Introduction 
Obesity is associated with the development of metabolic syndrome, a conglomerate of 
cardiometabolic risk factors, which synergistically result in cardiovascular diseases (CVDs), 
the major leading cause of death worldwide. The indigenous South African plant Rooibos 
(Aspalathus linearis), contains polyphenolic phytochemicals such as aspalathin, which is 
unique to Rooibos and has been associated with its health promoting properties. These include 
antidiabetic, anti-inflammatory, antioxidant, anti-obesity and cardiovascular benefits. Not 
much is known about the health promoting properties of Afriplex GRTTM, an aspalathin-rich 
Rooibos extract. It is hypothesised that Afriplex GRT™ may ameliorate the development of 
hypertension, vascular dysfunction and oxidative stress in a model of obese Wistar rats. 
Aim 
To investigate the ameliorative effect of Afriplex GRT™ extract on blood pressure, vascular 
function and oxidative stress in diet-induced obese Wistar rats.  
Methods 
Adult male Wistar rats were randomly divided into 5 experimental groups (n=10/group) and 
fed a Control or high-fat-diet (HFD), to induce obesity over a period of 16 weeks. Rats in the 
HFD and Control groups received the aspalathin-rich extract supplemented at 60 mg/kg/day 
from week 10 to 16. A Captopril (50 mg/kg/day) group was included as a positive control. 
Food and water intake, body weight, blood glucose, blood pressure, intraperitoneal (IP) fat 
mass, liver weight, leptin levels and vascular reactivity was measured. Western blotting of 
proteins involved in vascular function such as eNOS, AMPK and PKB were performed in aortic 
tissue. Antioxidant status and oxidative stress were determined in the liver tissue of 
experimental groups. This was done by measuring the activities of the primary antioxidant 
enzymes superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), and 
performing the thiobarbituric reactive substances (TBARS) assay which measures 
malondialdehyde as an indicator of lipid peroxidation. 
Results and Discussion 
HFD animals presented with increased food intake, leptin levels, body weight, glucose levels, 
IP fat and liver mass compared to Control animals. Furthermore, HFD animals had decreased 
Stellenbosch University  https://scholar.sun.ac.za
iv 
 
fluid intake and increased blood pressure vs the Control animals. Additionally, they presented 
with a downregulation in total and phosphorylated PKB and AMPK expression. HFD rats also 
had reduced SOD, CAT and GPx activity, increased malondialdehyde (MDA) levels and 
phosphorylated eNOS levels vs Control animals. Supplementation with GRT extract 
significantly decreased body weight, leptin levels, IP fat,  liver mass and improved glucose 
metabolism. Furthermore, it increased vasodilation, total eNOS expression, AMPK 
phosphorylation according to the AMPK ratio, whereas it decreased blood pressure. 
Additionally, it upregulated SOD, CAT and GPx activity and decreased MDA levels in the 
liver. Captopril decreased blood pressure, increased vasodilation and upregulated PKB, AMPK 
and eNOS expression. Therefore, supplementation with GRT extract alleviated the plethora of 
cardiovascular risk factors presented by the HFD animals.  
Conclusion  
The HFD model demonstrated detrimental effects on cardiovascular health. Treatment with the 
Afriplex GRTTM extract improved glucose metabolism, vascular function and antioxidant 
status in the HFD animals. Therefore, Afriplex GRT™ extract may be a potential therapeutic 
agent against obesity-related vascular dysfunction, impaired glucose homeostasis, elevated 
blood pressure and oxidative stress. 
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Opsomming 
Inleiding 
Vetsug word geassosieer met die ontwikkeling van metaboliese sindroom, 'n konglomeraat van 
kardiometaboliese risikofaktore, wat sinergisties lei tot kardiovaskulêre siektes (CVD's), die 
grootste oorsaak van die dood wêreldwyd. Die inheemse Suid-Afrikaanse plant, Rooibos 
(Aspalathus linearis), bevat polifenoliese fitochemikalieë soos aspalatien, wat uniek is aan 
Rooibos en geassosieer word met sy gesondheidsbevorderende eienskappe. Dit sluit in 
antidiabetiese, anti-inflammatoriese, antioksidant, anti-vetsug en kardiovaskulêre voordele. 
Nie veel is bekend oor die gesondheidsbevorderende eienskappe van Afriplex GRTTM, 'n 
aspalatienryke Rooibos-ekstrak, nie. Daar word gepostuleer dat Afriplex GRTTM die 
ontwikkeling van hipertensie, vaskulêre disfunksie en oksidatiewe stres kan verbeter in 'n 
model van vetsugtige Wistar-rotte. 
Doelstelling 
Om die verbeterende effekte van Afriplex GRT™ ekstrak op bloeddruk, vaskulêre funksie en 
oksidatiewe stres in dieet-geïnduseerde vetsugtige Wistar-rotte te ondersoek. 
Metodes 
Volwasse manlike Wistar-rotte is lukraak verdeel in 5 eksperimentele groepe (n = 10 / groep) 
en is ‘n Kontrole of hoëvet-dieet (HFD) gevoer om vetsug oor 'n tydperk van 16 weke te 
veroorsaak. Rotte in die HFD- en Kontrole groepe het die aspalatien-ryke ekstrak as aanvulling 
ontvang vanaf week 10 tot 16 teen 60 mg / kg / dag. 'n Captopril (50 mg / kg / dag) groep is as 
'n positiewe kontrole ingesluit. Voedsel- en waterinname, liggaamsgewig, bloedglukose, 
bloeddruk, intraperitoneaal (IP) vetmassa, lewergewig, leptienvlakke en vaskulêre reaktiwiteit 
is gemeet. Westerse klad tegnieke is uitgevoer om die uitdrukking van proteïene betrokke by 
vaskulêre funksie, soos eNOS, AMPK en PKB, in aortiese weefsel te bepaal. Antioksidant 
status en oksidatiewe stres is bepaal in die lewerweefsel van eksperimentele groepe. Dit is 
gedoen deur die aktiwiteite van die primêre anti-oksidant ensieme- superoksied dismutase 
(SOD), katalase (CAT), glutatioonperoksidase (GPx) te meet, en die tiobarbituursuur reaktiewe 
stowwe (TBARS) te toets wat malondialdehied meet as 'n aanduiding van lipiedperoksidasie. 
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Resultate en Gevolgtrekking 
HFD-diere het verhoogde voedselinname, leptienvlakke, liggaamsgewig, basale 
glukosevlakke, IP-vet en lewermassa in vergelyking met Kontrole-diere getoon. Verder het 
HFD-diere verminderde vloeistofinname, en verhoogde bloeddruk teenoor die Kontrole diere 
gehad. Daarbenewens het hulle 'n onderdrukking in totale en gefosforileerde PKB en AMPK 
uitdrukking getoon. HFD rotte het ook verlaagde SOD, CAT en GPx aktiwiteit, sowel as 
verhoogde malonaldialdehied (MDA) en gefosforileerde eNOS vlakke teenoor Kontrole diere 
getoon. Aanvulling met GRT ekstrak het tot beduidend verminderde liggaamsgewig, 
leptienvlakke, IP-vet, lewermassa en verbeterde glukose metabolisme gelei. Verder het dit 
vasodilatasie, totale eNOS-uitdrukking, sowel as AMPK-fosforilering volgens die AMPK-
verhouding verhoog, terwyl dit bloeddruk verlaag het. Daarbenewens het dit SOD, CAT en 
GPx aktiwiteit opreguleer en MDA-vlakke in die lewer verminder. Captopril het bloeddruk 
verminder, vasodilatasie bevorder en PKB-, AMPK- en eNOS-uitdrukking verhoog. 
Aanvulling met die GRT ekstrak het dus die oorvloed van kardiovaskulêre risikofaktore 
waarmee die HFD-diere gepresenteer het, verlig. 
Afsluiting  
Die HFD-model het nadelige uitwerking op kardiovaskulêre gesondheid getoon. Behandeling 
met die Afriplex GRT™ ekstrak het glukose metabolisme, vaskulêre funksie en antioksidante 
status in die HFD diere verbeter. Die Afriplex GRT™ ekstrak mag dus ŉ potensiële 
terapeutiese middel wees teen die behandeling van vetsugverwante vaskulêre disfunksie, 
verswakte glukose homeostase, verhoogde bloeddruk en oksidatiewe stres.  
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Chapter 1. Introduction and Literature 
Review 
1.1 Introduction  
Obesity is a major leading global health problem, more especially in the developing countries. 
It is mostly prevalent in the adult population, particularly in women (Baleta & Mitchell, 2014). 
Obesity is associated with the development of several non-communicable diseases (NCDs), 
such as cardiovascular diseases (CVDs). Risk factors for CVDs include hypertension, stroke, 
diabetes, dyslipidaemia, stroke, raised blood glucose, tobacco smoking, a sedentary lifestyle, 
ethnicity, ageing and a family history of CVDs (World Health Organization, 2017). Amongst 
the NCDs, CVDs contribute a large percentage of the global deaths annually, rapidly increasing 
in the low-to-middle income countries, increasing the health and socio-economic burden. 
Obesity prevalence is also associated with endothelial dysfunction (ED) and oxidative stress 
(World Health Organization, 2014).  
Plant and dietary polyphenols, have been shown to have ameliorative effects on the risk factors 
for CVDs. The Rooibos (Aspalathus linearis) plant in particular, has been of great interest as 
far as its health benefits are concerned and this includes its effect on cardiovascular health.  It 
is characterised by a rich polyphenolic composition, which includes aspalathin, a unique and 
major active flavonoid compound (Mikami, Tsujimura, Sato, Narasada, Shigeta, Kato, Hata & 
Hitomi, 2015). An accumulation of studies have shown that rooibos has numerous health 
promoting properties, such as anti-hypertensive, antidiabetic, anti-inflammatory, antioxidant, 
anti-cancer and anti-obesity effects (Mazibuko, Joubert, Johnson, Louw, Opoku & Muller, 
2015; Mikami et al., 2015; Persson, Persson, Hägg & Andersson, 2010). When the rooibos 
plant is harvested, it is processed into the fermented and unfermented product, which may be 
used to make herbal infusions (Ajuwon, Marnewick & Davids, 2015; Chen, Sudji, Wang, 
Joubert, Van Wyk & Wink, 2013). The polyphenolic composition of the unfermented rooibos 
is preserved and as a result, it has been used to produce aspalathin-rich rooibos extracts. The 
AfriplexTM GRT (GRT) extract used in this study, is a spray dried powder prepared from 
unfermented Rooibos. To date, no studies have been done investigating the relationship 
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between the ameliorative effects of the GRT extract on the obesity-induced CVD risk factors, 
therefore, more scientific investigation is needed.  
1.2 Cardiovascular Disease (CVD) 
1.2.1 Overview of CVD and Risk Factors  
CVD is defined as a group of heart and blood vessel disorders. The major contributors to CVD 
mortality are coronary heart disease (heart attack) and cerebrovascular disease (stroke). Heart 
attack and stroke occur when there is a blockage that obstructs blood flow to the heart or brain, 
respectively (World Health Organization, 2011) The blockage is mainly caused by the 
deposition of fatty material and cholesterol forming a plaque in the inner walls of the blood 
vessels supplying the heart and brain. Atherosclerosis is the underlying determinant of the 
development of heart attack and stroke (WHO, Federation & World Stroke Organization, 
2011). CVD risk factors can be classified into three categories, namely; social determinants 
and drivers (non-modifiable), modifiable behavioural risk factors which subsequently result in 
2nd cardiometabolic risk factors, if not well managed  (Fig 1.1) (World Health Organization, 
2011). 
 
Figure 1.1 Classification of the CVD risk factors (World Health Organization, 2011). 
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1.3 Epidemiology 
Non-communicable diseases (NCD) are highlighted as the leading cause of deaths globally, 
responsible for 40 million deaths (World Health Organization, 2017). It has been estimated that 
by the year 2030, global deaths due to NCD will increase to 52 million (World Health 
Organization, 2014). Approximately 16 million of the NCD affect individuals before the age 
of 70 and over 80% of these deaths occur in low-and-middle income countries and (Al-Mawali, 
2015). NCD include CVD (such as stroke and heart attacks), chronic respiratory disease 
(particularly asthma and chronic pulmonary obstructed disease), cancer and diabetes (Al-
Mawali, 2015). CVD are the leading cause of NCD deaths and are accountable for 
approximately 17.5 million deaths annually. An estimated 7.4 million were as a result of 
coronary heart diseases and 6.7 million were due to stroke. Secondary cause of NCD deaths is 
cancer, followed by chronic respiratory diseases and diabetes (Fig 1.2) (Mendis, Puska & 
Norrving, 2011; World Health Organization, 2017). In South Africa, by the year 2030, deaths 
due to cardiovascular diseases are expected to have increased by 41% in the working age group 
(35-64) (Steyn & Fourie, 2007). 
 
Figure 1.2 Global percentage distribution of NCD deaths that occurred before the age of 70 (Mendis 
et al., 2011). 
39%
27%
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4%
21%
Global NCD distribution
Cardiovascular diseases
Cancer
Respiratory diseases
Diabetes melitus
Other NCDs
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1.4 Obesity as an Independent Risk Factor for Mortality and 
Morbidity  
1.4.1  Overview and Epidemiology  
Obesity is defined as the energy imbalance between caloric intake as opposed to that which is 
expended (Ratzan, 2009). This results in enlarged adipose tissue because of the increased cell 
size (hypertrophy) and cell number (Hyperplasia) due to excess fat storage (Jo, Gavrilova, 
Pack, Jou, Mullen, Sumner, Cushman & Periwal, 2009). Excess accumulation of body fat 
impairs the health of an individual (Mollentze, 2006). Adipose tissue is a connective tissue that 
stores fat cells or adipocytes and also plays a role as an endocrine organ (Després & Lemieux, 
2006).  
Obesity is an independent CVD risk factor closely related to the consumption of high-energy 
dense foods, particularly a diet high in saturated fats, sugars, trans-fat cholesterol coupled with 
physical inactivity as opposed to low-energy dense foods. Obesity is a modifiable CVD risk 
factor through changing the diet to a well-balanced healthy diet and increasing physical 
activity. These changes subsequently reduce coronary heart diseases and other related CVD 
risk factors. Obesity is a global malady, affecting both adults and the children. In the year 2014, 
over 1.9 billion adults of 18 years and above were overweight and out of this, more than 600 
million were clinically obese. Approximately 42 million children over 5 years were clinically 
obese in 2013 (Ratzan, 2009). In South Africa in the year 2014, approximately 70% of women 
and  40 % of men were either obese or overweight (Baleta & Mitchell, 2014). 
1.4.2 Assessment and classification 
Obesity and overweight can be differentiated according to body mass index (BMI), calculated 
as body weight (Kg) divided by height (m2) of the individual (Ratzan, 2009). Obese and 
overweight persons have a BMI of ≥30 kg/m2 and >25 kg/m2, respectively (Table 1.1). 
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Table 1.1 Obesity classification in relation to health risk (Seidell & Flegal, 1997). 
Category BMI (kg/m2) Heath risk 
Underweight < 18.5 Increased 
Normal weight 18.5-24.9 Normal 
Overweight 25.0-29.9 Increased 
Class 1 obesity 30.0-34.9 Moderate 
Class 2 obesity 35.0-39.9 Severe 
Class 3 obesity 40.0-49.9 Extremely high 
Although BMI is a clinical method used to identify obese and overweight individuals. The 
major limiting factor of the BMI method is that, it does not directly measure the fat mass of an 
individual neither does it differentiate between muscle and fat mass. Therefore, BMI does not 
accurately measure obesity, especially intermediate obesity. Waist circumference (waist-to-hip 
ratio), however, is an alternative method that can be used to measure abdominal fat distribution. 
Definition of abdominal obesity according to waist circumference measurement differs 
according to gender. Men with a waist circumference greater than 40 (102 cm) are rendered to 
be abdominal obese and for women, a waist circumference greater than 35 (88 cm) (Seidell & 
Flegal, 1997). A larger waist circumference is directly proportional to an increased risk of 
developing multiple CVD risk factors even though BMI is well managed relative to individuals 
with normal waist circumference.  
1.5 Obesity and the Metabolic Syndrome 
Obesity, particularly abdominal obesity is associated with the development of metabolic 
syndrome (MS) and is an independent risk factor for the development of atherosclerotic CVD. 
MS is defined as a conglomerate of cardiometabolic risk factors that elevates CVD risk and 
Type 2 Diabetes (T2D) (Després & Lemieux, 2006; Jung & Choi, 2014). MS is characterised 
by insulin resistance, elevated blood pressure, glucose intolerance, atherogenic dyslipidaemia, 
and systemic inflammation (Fig 1.3) (Després & Lemieux, 2006; Grundy, 2004; Jung & Choi, 
2014). Obesity is also strongly associated with ED and the development of oxidative stress, as 
shown in Fig 1.3 (Todorovic & Mellick, 2015), resulting in atherosclerosis. 
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Figure 1.3 Association of obesity with metabolic syndrome and atherosclerotic cardiovascular 
disease. Interleukin 6 (IL-6), Nitric Oxide (NO) (MacFarlane et al., 2001). 
The mechanisms underlying the pathogenesis of obesity include modifications in insulin 
sensitivity, dyslipidaemia, ED and systemic inflammation (Després & Lemieux, 2006). The 
major driving factors whereby visceral obesity orchestrates the above mentioned metabolic and 
vascular disorders is through indirect and direct mechanisms. The indirect mechanism is 
facilitated by the development of insulin resistance (Caballero, 2003; Prieto, Contreras & 
Sánchez, 2014). Whereas, the direct mechanism, involves the secretion of adipokines such as 
chemokines, cytokines and hormones by the enlarged and inflamed adipose tissue (Jung & 
Choi, 2014; Xia & Li, 2017).  
1.6 Obesity and Adipose Tissue  
Adipose tissue is a connective tissue with dual function. It acts as a major storage site for excess 
energy in the form of triglycerides but is also considered to be an endocrine organ, secreting 
chemokines, cytokines and hormones (Jung et al., 2014; Kershaw et al., 2004). When energy 
is needed or in a fasting state, the triglycerides are broken down into free fatty acids (FFA) 
which enter into the various organs a source of energy. In an obese state, there is an increase 
in the release of pro-inflammatory cytokines, coupled with the downregulation of anti-
inflammatory adipokines and release of FFA into the circulation (Fig 1.4) (Skurk, Alberti-
Huber, Herder & Hauner, 2007). This is attributed to adipocyte hypertrophy as a result of 
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excess fat accumulation in the adipose tissue. The upregulated pro-inflammatory adipokines 
include interleukins (IL- 1, 6 & 18), plasminogen activator inhibitor type 1 (PAI-1), tumour 
necrosis factor alpha (TNF-α), leptin, resistin and angiotensinogen amongst others (Jung & 
Choi, 2014). The pro-inflammatory production, especially TNF-α, is facilitated by the 
macrophages and not particularly the adipocytes per se. Accumulation of macrophages is 
proportional to the adipose hypertrophy and in obesity, there is a macrophage conversion from 
anti-inflammatory (M2) to pro-inflammatory (M1) macrophages (Jung & Choi, 2014).    
The released FFA and pro-inflammatory cytokines, especially TNF-α and IL-1, 6 and 18, enter 
inside the liver and skeletal muscle and induce modifications in lipid and glucose homeostasis 
in these metabolic tissues, including modification in the inflammatory responses (Skurk et al., 
2007). This consequently induce insulin resistance, inflammation, dyslipidaemia, non-
alcoholic fatty liver diseases (NAFLD) and other metabolic syndrome characteristics (Boden, 
2008; Kim et al., 2014; Halberg et al., 2008). Additionally, this is also as a result of the impaired 
production of adiponectin, an insulin sensitizing adipokine that also possess anti-inflammatory 
effects. 
Leptin is a protein produced by the adipose tissue that regulates energy balance and body 
weight (Kouidhi, Jarboui, Clerget Froidevaux, Abid, Demeneix, Zaouche, Benammar Elgaaied 
& Guissouma, 2010; Marroquí, Gonzalez, Ñeco, Caballero-Garrido, Vieira, Ripoll, Nadal & 
Quesada, 2012). It is a hormone that controls appetite, food intake and energy expenditure.  
However, obese individuals are often at times rendered leptin resistant as a result of the 
increased circulating levels of leptin and the expression of its mRNA in the adipose tissue 
(Kouidhi et al., 2010). Leptin has also been shown to play a major role in glucose homeostasis 
irrespective of the appetite and food intake regulatory action (Marroquí et al., 2012). It 
improves insulin sensitivity in the liver, skeletal muscle and improves pancreatic β-cell 
function (Marroquí et al., 2012).  
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Figure 1.4 Role of the enlarged adipose tissue in the development of CVD risk factors  (Jung & Choi, 
2014). Monocyte chemoattractant protein-1 (MCP-1), Plasminogen activator inhibitor-1 (PAI-1), 
Retinol binding protein 4 (RBP4), Angiopoietin Like Protein 2 (ANGPTL2), Secreted frizzled-related 
protein 5 (SFRP5), Serum amyloid A (SAA), Severe acute pancreatitis (ASP) Tumor necrosis factor 
alpha (TNF-α), Transforming growth factor beta (TGF-β) and Interleukin (IL). 
1.7 Obesity and Insulin Resistance 
Insulin resistance is defined as the diminished ability of tissues to respond to insulin action 
(Caballero, 2003; Eringa, Bakker & van Hinsbergh, 2012). It is considered to be the integral 
feature of the MS, particularly such as T2D. Fig 1 (Muniyappa & Sowers, 2013; Turner, 2013). 
Insulin modulates glucose and lipid homeostasis by stimulating translocation of the glucose 
transporter 4 (GLUT4) to the plasma membrane, leading to the upregulation of glucose uptake 
by tissues, such as adipose tissue, skeletal muscle and the liver (Turner, 2013). In obesity, 
insulin action is compromised, consequently resulting to insulin resistance. During the insulin 
resistant state, the activation of downstream signalling pathways is compromised, thus 
resulting in an inadequate glucose uptake into tissues and a failure to decrease production of 
glucose by the liver. As a result, the pancreatic beta cells release more insulin into the 
circulation to compensate for the diminished insulin effectiveness which leads to 
hyperinsulinaemia, defined as too much insulin in the circulation (Taniguchi, Emanuelli & 
Kahn, 2006). Obesity-induced-insulin resistance in the adipocytes is linked to the dysregulated 
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release of pro-inflammatory and anti-inflammatory cytokines by the mature adipocytes and 
increased FFA production due to lipolysis. This leads to disrupted lipid homeostasis and 
NAFLD. Therefore, abnormal functioning of the adipose tissue adversely affects the 
physiological processes of the liver, heart and the skeletal muscle.  
Increased FFA in the circulation impairs insulin signalling and obese subjects have been shown 
to have increased FFA circulating in the plasma as opposed to lean individuals. Therefore, 
inhibition of lipolysis improves insulin sensitivity, and glucose tolerance in obese individuals. 
In lean adipose tissue, insulin has anti-lipolytic effects such that it stimulates the hydrolysis of 
adenosine 3',5'-cyclic monophosphate via activation of phosphodiesterase-3 stimulated by 
phosphatidyl inositol (PI) 3-kinase (PI3K), thus reducing the release of FFA from the 
adipocytes. When insulin is released into the circulation, it binds to the insulin receptor on 
peripheral insulin sensitive tissues and promotes the activation of the insulin receptor substrate 
(IRS). This leads to the activation of PI3K, subsequently inducing the phosphorylation of the 
protein kinase B (AKT/PKB kinase) signalling pathway. This pathway is responsible for 
regulation of glucose and lipid metabolism (Fig 1.5) (Taniguchi et al., 2006). 
 
Figure 1.5 Insulin signalling pathway in the adipose tissue. Insulin binding to its receptor initiates a 
cascade of signalling events upon phosphorylation of insulin receptor substrate (IRS) and AKT/PKB 
resulting in glucose and lipid metabolism alteration  (Jung & Choi, 2014). 
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1.7.1 AMP-activated protein kinase  
AMP-activated protein kinase (AMPK) is an insulin independent pathway, activated when the 
Thr172 is phosphorylated on the α-subunit is. Activation of AMPK is induced by nutrient 
deletion (particularly glucose), ischemia and hypoxic conditions. AMPK can also be activated 
plant polyphenols such as  quercetin and under oxidative stress conditions (Ahn, Lee, Kim, 
Park & Ha, 2008; Zmijewski, Banerjee, Bae, Friggeri, Lazarowski & Abraham, 2010). When 
activated, it elicits multiple functions in various organs, such as the liver, skeletal muscle, 
pancreatic islets and the adipocytes counteracting the pathophysiological-induced metabolic 
dysfunction. In the liver, it increases fatty acid oxidation, decreases synthesis of cholesterol 
and lipogenesis. Whereas in the skeletal muscle, it increases glucose uptake and oxidation of 
fatty acids. In the pancreatic islets it modulates the secretion of insulin and decreases 
lipogenesis and lipolysis in the adipocytes. Therefore, AMPK is considered an important 
potential therapeutic target for the treatment of obesity, T2D and cancer (Hardie, 2004; Kim, 
Jung, Son, Kim, Ha, Park, Jo, Park, Choe, Kim & Ha, 2007; Kim, Yang, Kim, Kim & Ha, 
2016; Kim, 2015). It also stimulate the production of NO by inducing the phosphorylation of 
endothelial nitric oxide synthase (eNOS) in cultured endothelial cells (Zhang, Lee, Kolb, Sun, 
Lu, Sladek, Kassab, Garland & Shyy, 2006).  
1.8 Obesity and NAFLD 
NAFLD is categorised into two, steatosis and steatohepatitis, which progress to cirrhosis and 
liver failure if not reversed. It is one of the chronic liver diseases characterised by an increase 
in serum aminotransferase (Farrell & Larter, 2006; Kumar & Mohan, 2017). Obesity is 
regarded as a common cause or primary initiator of NAFLD development. Studies conducted 
in humans, have shown a positive correlation between the development of steatosis and 
steatohepatitis and increasing BMI (Choudhary, Duseja, Kalra, Das, Dhiman & Chawla, 2012; 
Mittendorfer, Magkos, Fabbrini, Mohammed & Klein, 2009; Ruhl & Everharty, 2003).  
On the other hand, insulin resistance has been proven to play a significant role in the 
pathogenesis of NAFLD, especially in obese subjects (Farrell & Larter, 2006). Acute 
accumulation of triglycerides in the liver is the initial phase to the development of NAFLD. 
This leads to dysregulation of lipid, glucose and lipoprotein metabolism. Secondly, triglyceride 
accumulation predispose the liver to inflammation, fibrosis and hepatic injury. The 
development of the second phase is often characterised by the imbalance in pro-inflammatory 
and anti-inflammatory cytokine secretion, mitochondrial and oxidative damage and subsequent 
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lipid peroxidation (Fabbrini, Sullivan & Klein, 2010; Jung & Choi, 2014). An accumulation of 
studies have shown that NAFLD is strongly associated the development of T2D, dyslipidaemia 
and hypertension (Adams, Lymp, St. Sauver, Sanderson, Lindor, Feldstein & Angulo, 2005). 
The development of NAFLD is also driven by genetics, and ethnic background (Adams et al., 
2005). NAFLD progression can be effectively reversed by reduction of weight gain, especially 
visceral obesity and by adopting a healthy lifestyle consequently improving insulin resistance, 
inflammation, fibrosis, steatosis and hepatic injury.  
1.9 The Endothelium 
The endothelium is classified as an epithelial tissue lining the interior surface of the blood 
vessels and plays a major role in vascular homeostasis preventing the development of 
atherosclerosis (Tang & Vanhoutte, 2010). It also maintains vascular homeostasis by secreting 
different vasoactive molecules that function to either constrict or dilate the vasculature in 
response to stimuli (Rajendran, Rengarajan, Thangavel, Nishigaki, Sakthisekaran, Sethi & 
Nishigaki, 2013; Tang & Vanhoutte, 2010).  
1.9.1 Endothelial Function  
The endothelium maintains vascular homeostasis through a variety of functions. These include 
the regulation of vascular tone, vascular growth, inhibition of platelet-leukocyte aggregation, 
control of vascular inflammation, thrombosis and thrombolysis (Rajendran et al., 2013). These 
functions are carried out by the endothelium by secreting a variety of endothelium-derived 
vasoactive factors summarised in Table 1.2 (Mudau, Genis, Lochner & Strijdom, 2012; 
Rajendran et al., 2013). However, vascular maturity is mediated by the vascular endothelial 
growth factors (VEGF) secreted by endothelial cells (Rajendran et al., 2013).  
The endothelium maintains the vascular tone by secreting vasodilatory factors, nitric oxide 
(NO) and prostacyclin (PGl2) (Naruse, Rask-Madsen, Takahara, Ha, Suzuma, Way, Jacobs, 
Clermont, Ueki, Ohshiro, Zhang, Goldfine & King, 2006; Rajendran et al., 2013). Endothelial 
cells not only secrete vasodilators but endothelium-derived vasoconstrictors, which include 
reactive oxygen species (ROS), endothelin-1 (ET-1) and thromboxane A2 (Pober & Sessa, 
2007; Vanhoutte, Shimokawa, Tang & Feletou, 2009). These molecules have a positive effect 
on, the internal alteration of the blood vessel calibre (vasomotion), cell growth and proliferation 
of endothelial and vascular smooth muscle cells (VSMC) when at normal levels (Pober & 
Sessa, 2007). In summary, the vasodilatory state entails an enhanced antioxidant activity, an 
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anti-inflammatory state, thrombolysis and platelet disaggregation. Vasoconstriction on the 
other hand entails, thrombolysis, adhesion molecules, growth factor, inflammation and 
increased oxidant activity (Strijdom, Chamane & Lochner, 2009; Strijdom & Lochner, 2009). 
1.10 Endothelium-Derived Factors 
1.10.1 Nitric Oxide (NO) 
Nitric oxide (NO) is a potent endothelium-derived vasodilator of the underlying vascular 
smooth muscle and was discovered in the 1980’s (Sandoo, van Zanten, Metsios, Carroll & 
Kitas, 2010). It is synthesised by the nitric oxide synthase (NOS) enzyme by converting L-
arginine amino acid to NO and L-citrulline. NOS enzyme is comprised of three different 
isofoms, neuronal (nNOS), inducible (iNOS) and endothelial isoform (eNOS). The neuronal 
isoform produces NO so to act as a neuronal messenger to stimulate the release of 
neurotransmitter (Schwartz & Kloner, 2011; Strijdom & Lochner, 2009), inducible isoform 
expressed only in injured cells which are exposed to inflammatory mediators thus activating 
macrophages and eNOS produces NO in the blood vessels (Bryan, Bian & Murad, 2009; 
Strijdom et al., 2009). Dilation of blood vessels is dependent on the activation of eNOS. When 
inactive, eNOS remains bound to the caveolin-1 protein which is arranged in small caveolae or 
pockets localised in the cell membrane. eNOS is activated when intracellular calcium levels 
increase, causing eNOS to detach from the caveolae. The activated eNOS stimulates the release 
of NO by concerting L-arginine to NO (Fig 1.6) (Bae, Kim, Cha, Park, Jo & Jo, 2003).  
Activation of eNOS can also be elicited by NO agonists which stimulate the release of calcium 
from the endoplasmic reticulum. These agonists include; bradykinin, acetylcholine, adenosine 
tri-phosphate (ATP), adenosine di-phosphate (ADP), cyclic guanosine monophosphate 
(cGMP). Another mechanism that leads to NO production through eNOS activation is sheer 
stress (Boo & Jo, 2003). Sheer stress ensures NO production via two processes; it initiates 
phosphorylation of eNOS via PKB, guanylate cyclase (cGC) and cGMP and through activation 
of the specialised calcium channels that cause an efflux of the K+ ions and an influx of Ca2+ 
(Boo, Sorescu, Boyd, Shiojima, Walsh, Du & Jo, 2002). The NO produced diffuses from the 
endothelial cell to the underlying VSMC and activates the soluble cyclic guanylyl cyclase 
enzyme (Fig 1.6). 
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Table 1.2 An overview of the endothelin-derived vasoactive factors (Mudau, Genis, Lochner & 
Strijdom, 2012).  
Endothelium-derived factors  
 
Physiological effects Enzymatic source and 
mechanism of action 
NO • Potent vasodilator. 
• Inhibits inflammation, VSMC 
proliferation and migration, 
platelet aggregation and 
adhesion, and leukocyte 
adhesion. 
• Regulates myocardial 
contractility.  
• Regulates cardiac metabolism. 
• Cardioprotective during 
ischaemia-reperfusion injury. 
• It is synthesised by the 
enzymes: eNOS, nNOS and 
iNOS, with eNOS being the 
major source of NO during 
physiological conditions in 
the endothelium. 
• Diffuses from endothelial 
cells to underlying VSMCs 
where it binds to an 
enzyme, soluble guanylyl 
cyclase, leading to a 
cascade of events that 
ultimately result in vascular 
relaxation. 
Prostacyclin (PGI2) • Vasodilatory agent. 
• Inhibits platelet aggregation. 
• Derived from arachidonic 
acid by enzyme 
cyclooxygenase-2 (COX-
2). 
Endothelium-derived 
hyperpolarising factor 
(EDHF) 
• Exerts vasodilatory effects, 
particularly in small arteries of 
diameter ≤ 300 µm. 
• Its identity is still under 
suspicion with proposed 
candidates such as 
potassium ions and, 
hydrogen peroxide. 
• Causes relaxation of 
VSMCs by means of 
membrane 
hyperpolarisation. 
Endothelin-1 (ET-1) • A potent vasoconstrictor.  • Synthesised by endothelin-
converting enzyme. 
• Exerts its effects via two 
receptors: ETA expressed 
on endothelial cells and 
ETB on VSMCs. ETA 
receptors promote 
vasoconstriction, whereas 
ETB receptors promote NO 
production and ultimately 
reduction in ET-1 
production. 
Thromboxane A (TXA2) • A potent vasoconstrictor. • Derived from arachidonic 
acid by enzyme COX-1. 
Angiotensin II • A potent vasoconstrictor. • Synthesised by angiotensin 
converting enzyme. 
• Elicits its effects via two 
receptors: AT1 which 
promotes vasoconstriction 
and cell proliferation, and 
AT2 which antagonises the 
effects of AT1.   
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When activated, it enhances the conversion of the guanosine triphosphate (GTP) to cGMP, 
which leads to the vasodilation of VSMC (Fig 1.6) (Bae, Kim, Cha, Park, Jo & Jo, 2003). 
Low calcium levels lead to the dissociation of eNOS from the calcium-calmodulin complex 
thus binding to the caveolae and becomes inactive. eNOS and iNOS are calcium dependent 
enzymes. This is in contrast to nNOS, which is calcium-independent and produces NO 
constitutively in low levels (Strijdom, Chamane & Lochner, 2009). nNOS produces high levels 
of NO, relatively about 1000-fold more than iNOS and eNOS. This in turn can be dangerous 
for the cell as NO can bind to the O2
•- free radical, producing peroxynitrite, a highly reactive 
free radical (Strijdom et al., 2009).  
 
Figure 1.6 The production of endothelial nitric oxide and its function in the smooth muscle 
cell (Sandoo, van Zanten, Metsios, Carroll & Kitas, 2010). Acetylcholine (ACh), adenosine 
triphosphate (ATP), adenosine diphosphate (ADP), bradykinin (BK), cyclic guanosine-3’, 5-
monophosphate (cGMP), endothelial nitric oxide (eNOS), endoplasmic reticulum (ER), 
soluble guanylyl cyclase (sGC), Guanosine-5'-triphosphate (GTP),  myosin light chain kinase 
(MLCK), nitric oxide (NO), store-operated Ca2+ channel (SOCa2+), substance P (SP). 
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1.10.2 Endothelin-1 (ET) 
Endothelin (ET) is classified as a potent vasoconstrictor of the endothelium and has 3 isoforms; 
ET-1, ET-2 and ET-3. ET-1 is however, the only endothelin which is expressed in the 
endothelium. The three types of ET-1 receptors are located in the endothelium (ETB1) and in 
the smooth muscle cell (ETA and ETB2). ET-1 release and production is regulated by 
inflammatory cell mediators (TNF-α, interleukin-1 and chemokines) and a decrease in NO 
However, it has been shown that sheer stress decreases the expression of ET-1 (Böhm & 
Pernow, 2007). In the normal physiological state, ET-1 binds to ETA and ETB2 receptors 
causing the calcium smooth muscle channels to open thus allowing an influx of the 
extracellular calcium into the cells, which leads to vasoconstriction. When ET-1 binds to the 
ETB1 receptors in the endothelium, it elicits a vasodilatory response via the stimulation of NO 
release (Sud & Black, 2009). 
ET-1 is upregulated in cardiovascular risk factors such as and diabetes mellitus obesity (Weil, 
Westby, Van Guilder, Greiner, Stauffer & DeSouza, 2011). Production of ET-1, a 
vasoconstrictor, is another underlying cause of ED (discussed in 1.11) in obesity and  ET-I is 
highly expressed in obese individuals with metabolic syndrome (Prieto, Contreras & Sánchez, 
2014). In patients with ED (as result of decreased NO bioavailability) it has been shown that 
blocking the ETA and ETB2 receptors leads to vasodilation. This means that in ED, the ETB1 
receptors in the endothelium are downregulated while the ETB2 are upregulated subsequently 
resulting in enhanced vasoconstriction (Böhm & Pernow, 2007) An increase in ET-1 
expression results in the reduction of eNOS expression which leads to decreased NO 
production via a protein kinase C (PKC) mechanism (Sud & Black, 2009). 
1.10.3 Angiotensin II (Ang II) 
Angiotensin II (Ang II) is metabolised from angiotensin I by angiotensin converting enzyme 
(ACE). It is a potent vasoconstrictor that plays a key role in the development of ED, a common 
feature of hypertension (Tang & Vanhoutte, 2010). When bound to the angiotensin receptors, 
it triggers an increase in extracellular calcium, thus mediating vasoconstriction. Ang II also 
increases the production of ROS through the activation of Nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase and the membrane bound NADPH. Furthermore, it directly 
stimulates the release of endothelin-I, thus aggravating ED (Zhang, Dellsperger & Zhang, 
2012).  
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1.11 Endothelial dysfunction  
Endothelial dysfunction (ED) is defined as an imbalance between the production of 
vasodilatory and vasoconstriction factors acting on the endothelium. ED is considered to be an 
early predictor or precursor of atherosclerosis and is characterised by a decrease in the 
bioavailability of NO (Sena, Pereira & Seiça, 2013; Tang & Vanhoutte, 2010).   
Development of ED is associated with chronic exposure to CVD risk factors and the harmful 
stimuli associated with these factors (Mudau, Genis, Lochner & Strijdom, 2012; Sena et al., 
2013). The CVD risk factors include hypertension, dyslipidaemia, diabetes mellitus, smoking, 
physical inactivity, obesity and aging (Yang et al., 2010). The harmful stimuli include the 
secretion of adipokines, pro-inflammatory cytokines (TNF-α, IL-1, Ang II), increased FFA, 
including oxidised low-density lipoprotein (LDL), hyperglycaemia and ROS (Mudau et al., 
2012). 
ED is the most common feature in obese and overweight individuals. The inflamed adipose 
tissues in an obese state release proinflammatory cytokines in large amounts, which 
consequently interferes with insulin signalling in endothelial cells and downregulation of NO 
signalling (eNOS phosphorylation) (Aghamohammadzadeh, Unwin, Greenstein & Heagerty, 
2016). Reduction of eNOS enzyme expression, eNOS uncoupling (due to reduction in substrate 
availability) and increased NO scavenging by O2
•- anions are the underlying mechanisms 
responsible for the reduction of NO production (Bakker, Eringa, Sipkema & van Hinsbergh, 
2009; Kobayasi, Akamine, Davel, Rodrigues, Carvalho & Rossoni, 2010). The development 
of oxidative stress has been shown to be one of the causes of ED in obese individuals due to 
elevated O2
•- production which binds with NO forming peroxynitrite, a highly reactive free 
radical responsible for eNOS uncoupling (Li & Förstermann, 2013; Li, Horke & Förstermann, 
2014; Wolin, 2000).  
1.11.1 Endothelial dysfunction and Hypertension 
In the hypertensive state, the balance between the production of the vasodilators and 
vasoconstrictors produced by the endothelium is disturbed. This includes the NO pathway and 
subsequently vasoconstriction factors like ET-1 dominate, resulting in elevated high blood 
pressure (Bernatova, 2014; Lobato, Filgueira, Akamine, Tostes, Carvalho & Fortes, 2012). 
Anti-hypertensive drugs, that act to inhibit the ACE such as Captopril can improve vascular 
function, oxidative stress and stimulate the secretion of bradykinin in order to increase NO 
bioavailability (Franzini, Ardigò, Valtueña, Pellegrini, Del Rio, Bianchi, Scazzina, Piatti, 
Stellenbosch University  https://scholar.sun.ac.za
17 
 
Brighenti & Zavaroni, 2012; Rizos, 2014). Patients with diabetes have characteristically low 
NO bioavailability, resulting from increased oxidative stress levels (Li & Förstermann, 2013; 
Li, Horke & Förstermann, 2013). Studies have shown a positive correlation between the intake 
of ACE inhibitors and endothelial function, through an increase in NO bioavailability and a 
decrease in oxidative stress in type 1 diabetic patients (Gillespie, White, Kardas, Lindberg & 
Coleman, 2005; Li, Heran & Wright, 2014). Patients with hypertension have low NO levels, 
high expression of the vasoconstriction factors (ET-1, Ang II and TXA2) and elevated ROS 
production (Tang & Vanhoutte, 2010). Upon vasodilatory stimuli (acetylcholine and 
bradykinin), patients with hypertension had poor forearm mediated blood flow and this also 
indicated ED (Tang et al., 2010). A study showed an impairment in the PKB independent 
activation of eNOS in a hypertensive rat model (Iaccarino, Ciccarelli, Sorriento, Cipolletta, 
Cerullo, Iovino, Paudice, Elia, Santulli, Campanile, Arcucci, Pastore, Salvatore, Condorelli & 
Trimarco, 2004).  
1.11.2 Endothelial Dysfunction and Oxidative Stress 
Amongst the CVD risk factors, oxidative stress is the major leading cause of ED which is 
characterised by increased production of ROS, particularly the O2
•- . NADPH oxidase, xanthine 
oxidase and the mitochondria and are the well-known ROS sources and ROS production results 
in VSMC growth (thickening of the vascular wall) and apoptosis of the endothelium (Iaccarino 
et al., 2004).The O2
· free radical is scavenged by the superoxide dismutase (SOD) endogenous 
antioxidant enzyme to H2O2 (Pennathur & Heinecke, 2007). Increased production of the O2
· 
overwhelms the SOD antioxidant enzyme and tends to couple with NO produced, forming 
peroxynitrite, a highly reactive nitrogen species (RNS). This process is defined as eNOS 
uncoupling, whereby eNOS acts as a free radical generator in the presence of high O2
- levels. 
The O2
- has high affinity with NO compared to SOD, which perpetuates the production of 
peroxynitrite. Increased levels of peroxynitrite in turn damages the cell DNA, lipids and 
proteins (Landmesser, Harrison & Drexler, 2006). 
1.12 Hypertension 
1.12.1 Overview and Epidemiology 
Hypertension occurs when the blood pressure is greater or equal to ≥140/90 mmHg, systolic 
and diastolic, respectively. Blood pressure is defined as the force of blood pushing against the 
walls of the arteries. Hypertension forms part of the CVD risk factors and is often regarded as 
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a silent killer such that the symptoms are not apparent in the early stages resulting to individuals 
being undiagnosed. It is most prevalent in the low-and-middle income countries and prevalence 
increases with age. In 2014, approximately 22% adults (>18 years and above) were 
hypertensive (WHO, 2014) and 21% adults in South Africa were hypertensive, women 
contributing a large percentage, relative to men (Steyn, Gaziano, Bradshaw, Laubscher & 
Fourie, 2001). 
1.12.2 Primary Causes of Hypertension  
Causes of hypertension can be classified into two categories, primary and secondary. 
Secondary causes are as a result of the primary causes. The primary causes include behavioural 
risk factors, such as, sedentary lifestyle, physical inactivity, chronic consumption of alcohol, 
and tobacco use (Fig 1.1). Reduction in salt intake also plays a vital role in preventing the 
development of hypertension, including the behavioural risk factors especially BMI < 25 kg/m2 
maintenance. 
1.12.3 Secondary Causes of Hypertension 
The major instigator of hypertension is abdominal obesity (Ritchie & Connell, 2007). Obesity-
induced hypertension leads to impaired renal pressure natriuresis mechanism, defined as the 
relationship between excretion of sodium and mean arterial pressure (Hall, Do Carmo, Da 
Silva, Wang & Hall, 2015; Hall, Da Silva, Do Carmo, Dubinion, Hamza, Munusamy, Smith & 
Stec, 2010). In hypertensive patients, it has been shown that this mechanism maintains sodium 
excretion and water intake, resulting in an increased mean arterial pressure (Jung & Choi, 2014; 
Lobato, Filgueira, Akamine, Tostes, Carvalho & Fortes, 2012). Several studies have shown 
that activation of the sympathetic nervous system, activation of the renin angiotensin 
aldosterone activation system (RAAS) and renal compression, due to accumulation of fat inside 
and around the kidney impair renal pressure natriuresis (Chandra, Neeland, Berry, Ayers, 
Rohatgi, Das, Khera, McGuire, De Lemos & Turer, 2014; Thethi, Kamiyama & Kobori, 2012). 
Increased leptin levels is another mechanism that elevates blood pressure via activation of the 
sympathetic nervous system, thus inducing renal failure. Activation of the sympathethic 
nervous system and fat accumulation inside the kidneys have also been associated with RAAS 
activation. A deficiency in the natriuretic peptide has been correlated with the poor sodium and 
water excretion (Asferg, Nielsen, Andersen, Linneberg, Møller, Hedley, Christiansen, Goetze, 
Esler & Jeppesen, 2013). Previous studies have documented a deficiency in the atrial natriuretic 
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peptide in hypertensive obese individuals when compared to lean normotensive individuals 
(Wang, Larson, Levy, Benjamin, Leip, Wilson & Vasan, 2004). Human studies have shown a 
positive correlation between visceral, renal adiposity and hypertension (Chandra et al., 2014; 
Chughtai, Morgan, Rocco, Stacey, Brinkley, Ding, Nicklas, Hamilton & Hundley, 2010). 
Ang II plays a major role in mediating hypertension by stimulating sodium reabsorption. 
Previous studies done in diet-induced obese animals have shown an attenuated response in 
increased blood pressure and sodium retention when ACE is inhibited (Boustany, 2005). In 
addition, inhibition of the RAAS system may serve as potential therapeutic strategy for 
hypertension, dyslipidaemia and impaired glucose homeostasis (Putnam, Shoemaker, 
Yiannikouris & Cassis, 2012).  
Other pathophysiological causes of the obesity-induced hypertension, subsequently resulting 
to renal injury include insulin resistance, dylipidemia, glucose intolerance and inflammation 
(Engeli, 2005). In an obese state, the inflamed adipocytes release adipocytokines in significant 
amounts, which subsequently induce the development of hypertension and metabolic syndrome 
via different pathways as that depicted in Fig 1.7. (Katagiri, Yamada & Oka, 2007). 
 
Figure 1.7 Mechanisms associated with development of hypertension in obese state. interleukin-6 (IL-
6); non-esterified fatty acids (NEFA), obstructive sleep apnea (OSA) and tumor necrosis factor-α 
(TNF-α), (Yanai, Tomono, Ito, Furutani, Yoshida & Tada, 2008). 
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1.13 Activation of Renin-Angiotensin-System  
Activation of the RAS is common in obesity and it plays a major role in blood pressure 
regulation and fluid homeostasis (Thethi et al, 2012). RAAS activation is stimulated by the 
production of adipocytokines (angiotensinogen), sympathetic stimulation, hyperinsulinemia 
and structural changes in the kidney, as well as adverse changes in sodium retention (Thethi et 
al., 2012). Angiotensinogen is highly expressed in adipocytes which results in increased levels 
of angiotension II production (Engeli, Schling, Gorzelniak, Boschmann, Janke, Ailhaud, 
Teboul, Massiéra & Sharma, 2003). Hence studies have found a high expression of ACE and 
angiotensin type 1 receptor in adipose tissues (Engeli et al., 2003).  
1.14 Oxidative Stress  
1.14.1 Overview  
Oxidative stress occurs when there is an imbalance between the normal cellular production of 
pro-oxidants and endogenous antioxidant enzymes and plays a major role in the pathogenesis 
of numerous diseases such as CVD and risk factors thereof,  such as ED (Ajuwon, Marnewick 
& Davids, 2015). 
Pro-oxidants are primarily composed of free radicals, defined as ions or atoms that have a non-
paired electron on the outer orbital, thus rendered to be highly reactive. The highly reactive and 
unstable nature of the free radicals lead to generation of more free radicals. This occurs when 
they bind to macromolecules in search for electrons to complete the outer orbital, resulting to 
oxidation of the macromolecules. Sources of free radicals are; oxygen, nitrogen, chlorine and 
sulphur. When they react with oxygen and nitrogen, they form ROS and RNS, respectively. 
ROS and RNS are essentially produced as by-products by aerobic organisms during normal 
metabolism, their examples are listed in Table 1.3 (Ajuwon, Oguntibeju & Marnewick, 2014).  
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Table 1.3 Reactive oxygen species and reactive nitrogen species (Ajuwon, Marnewick & Davids, 
2015; Dhawan, 2014).  
ROS RNS 
Radicals 
Superoxide: O2
·- 
Hydroxyl: OH· 
Peroxyl: ROO· 
Alkoxyl: RO· 
Hydroperoxyl: HOO· 
Nitric oxide: NO· 
Nitrogen dioxide: NO2
· 
 
Non-radicals 
Hydrogen peroxide: H2O2 
Hypochlorous acid: HOCL 
Hypobromus acid: HOBr 
Peroxynitrite: ONOO- 
Ozone: O3 
 
Peroxynitrite: ONOO- 
Alkyl peroxynitrites: ROONO 
Nitrogen dioxide: NO2 
Nitrosonium cation: ⋅NO2 
Nitroxyl anion: NO- 
Nitronium anion: NO2
+   
1.14.2 ROS  
ROS are exceptionally reactive species containing oxygen and their production can be triggered 
by a variety of sources classified as endogenous or exogenous as listed in Table 1.4. ROS are 
primarily produced by the mitochondria via the mitochondrial electron transport chain, 
complex I and III being the major production sites. These complexes produce ROS in the 
mitochondrial matrix in the form of O2
•- radical, during energy transduction. Other important 
production sites for ROS include xanthine oxidase, NADPH oxidase and eNOS uncoupling 
(Dhawan, 2014).  
The ROS have both beneficial and harmful effects depending on the concentration status. When 
produced in normal or moderate physiological concentrations ROS exert beneficial effects, 
such as, acting as signalling molecules, protect against environmental pathogens by functioning 
as mediators of inflammation and they play a role in maintaining vascular tone via cGMP 
(Dröge, Granner & Boveris, 2002; Li, Horke & Förstermann, 2014; Pourova, Kottova, 
Voprsalova & Pour, 2010; Valko, Leibfritz, Moncol, Cronin, Mazur & Telser, 2007). However, 
when the mitochondrial electron transport chain is impaired, primarily due to a 
pathophysiological condition, excess ROS is generated as a by-product. Excess production of 
ROS in the biological system often induce oxidative stress which results in the degradation of 
lipids, membranes, proteins and nucleic acids (Scherz-Shouval & Elazar, 2011). 
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Table 1.4 Sources of pro-oxidants (Ajuwon, Marnewick & Davids, 2015).  
Exogenous Endogenous  
High-calorie diet  
Excessive alcohol intake  
Tobacco smoke  
Radiation (UV and X-rays) 
Environmental pollutants (heavy metals, N-
containing compounds 
Strenuous exercise and psychological stress 
Mitochondrial electron transport chain  
Phagocytosis 
Neutrophils and macrophages during 
inflammation 
Xanthine oxidase 
NADPH oxidase 
eNOS uncoupling 
Oxidation of haemoglobin 
Enzyme activity including cytochrome 
P450 system  
1.14.3 Antioxidants 
Antioxidants play a role in anti-oxidant defence system by regulating the balance between ROS 
production and their elimination. They can either be endogenous or exogenous produced and 
further classified as enzymatic or non-enzymatic substances (Table 1.5).  
Table 1.5 Classification of antioxidant defence system components (Ajuwon et al., 2015). 
Endogenous  Exogenous  
Non-enzymatic 
Thiols (glutathione, lipoic acid, N-acetyl 
cysteine) 
Ubiquinones (coenzyme Q10) 
Uric acid 
Bilirubin 
Transferrin 
Albumin 
Carotenoids (β-carotene) 
Vitamin C 
Vitamin E 
Vitamin A 
Plant phenols (flavonoids and other 
polyphenol types)  
Metals (copper, manganese, selenium and 
Zinc) 
Enzymes 
Superoxide dismutase (SOD) 
Catalase (CAT) 
Glutathione peroxidase (GPx) 
Glutathione reductase  (GR) 
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1.14.3.1 Endogenous Antioxidant Enzymes  
Endogenous enzymes are localised in different areas, functioning to protect the cells against 
oxidative damage. These innate antioxidant enzymes can be classified as SOD, catalase (CAT), 
glutathione peroxidase (GPx) and glutathione reductase (GR) (Table 1.5).  
O2
·- is considered a primary and highly reactive ROS radical produced by the mitochondria 
during energy transduction. Other sources of O2
·- include uncoupled eNOS, xanthine and 
NADPH oxidase. O2
·- radical is converted by the SOD into a less reactive compound, hydrogen 
peroxide (H2O2). SOD can be classified in to 3 main types; Mitochondrial SOD (MnSOD), 
cytosolic copper/zinc (Cu/Zn) SOD and extracellular SOD. The extracellular SOD is localised 
in the interstitial spaces of tissues and extracellular fluids, primarily responsible for the SOD 
activity in the plasma. They function to dismutate the O2
·- radical in various areas to protect 
the cells from oxidative damage (Pamplona & Costantini, 2011).  
H2O2 is further metabolised into H2O and oxygen by the CAT enzyme and also by the 
glutathione coupled enzyme reaction. The glutathione coupled enzyme reaction consist of GPx, 
GR and glutathione. Glutathione is the most abundant thiol found in all the cells. In most cells, 
it exist as reduced glutathione (GSH) and functions to detoxify hydroperoxides. Increased GSH 
cellular levels may be an indicator of the pathophysiological changes. The glutathione coupled 
enzyme reaction hydrolyses H2O2 by using the GSH as a substrate and is oxidised to glutathione 
disulphide (GSSG) by GPx. GSH is in turn regenerated via NADPH oxidation by the GR. This 
reaction is rendered the most important pathway in H2O2 metabolism in most cells and provides 
protection against oxidation of lipids (Pamplona & Costantini, 2011). 
1.14.3.2 Exogenous Antioxidant Enzymes 
Excessive ROS production including other free radicals tend to overwhelm the innate 
antioxidant enzyme system, as result, additional exogenous antioxidant defence system is often 
required (Ajuwon, Marnewick & Davids, 2015). Examples of the exogenous antioxidants, 
often derived from the diet, include vitamin C (ascorbate), E, A and carotenoids (Table 1. 5). 
Vitamin C is the most abundant non-enzymatic antioxidant in the cells and is often compared 
glutathione. Ascorbate opposes accumulation of ROS and free radicals by donating an electron 
to their outer orbital, forming an ascorbate radical (Asc-). Asc- is later converted to its former 
state by NADH- and NADPH-dependent dehydroascorbate reductase and GSH-dependent 
dehydroascorbate reductase (Wells & Xu, 1994). Vitamin E and carotene protect the cells 
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against lipid oxidative damage by decreasing the formation of peroxyl to hydroperoxides 
groups, thus inhibiting the propagation of lipid peroxidation (Brigelius-Flohe & Traber, 1999; 
Esterbauer, Schaur & Zollner, 1991; Pamplona & Costantini, 2011). Plant phenolics also play 
a major role in the exogenous antioxidant defence system by protecting the cells against 
oxidative damage. Their numerous health effects are mainly attributed to their polyphenolic 
content (Liu, 2003). These polyphenols are mostly found in teas, fruits, vegetables, spices and 
have been proven to possess ameliorative effects on the CVD risk factors and cancer (Weng & 
Yen, 2012). 
1.15 Lipid Peroxidation 
Lipid peroxidation is an oxidative degradation of lipids that occurs when the ROS bind to lipids 
on the cellular membrane by removing the lipid bound hydrogen molecule, resulting in cellular 
injury. These ROS include O2
·-, ONOO, and OH. They form lipid radicals by binding to the 
double-carbonated fatty acids on the cell membrane. To stabilise themselves, they bind to 
oxygen forming peroxyl radical, which later oxidises the neighbouring fatty acids turning into 
a stable lipid hydroperoxide. The oxidised neighbouring fatty acids propagate the process by 
oxidising lipids across the cell membrane thus forming multiple lipid hydroperoxides (Jomova, 
Jenisova, Feszterova, Baros, Liska, Hudecova, Rhodes & Valko, 2011; Valko, Rhodes, 
Moncol, Izakovic & Mazur, 2006). The generation of these lipid peroxidation is later converted 
to unstable conjugated dienes that give rise end products that are stable, malondialdehyde 
(MDA). MDA is the most common example of oxidative stress biomarker and is often used to 
quantify and access oxidative damage in the cell (Dalle-Donne, Rossi, Colombo, Giustarini & 
Milzani, 2006).  
1.16 Rooibos (Aspalathus linearis) 
1.16.1 Overview  
Rooibos (Aspalathus linearis) is a leguminous shrub indigenous to the Cederberg Mountains 
of the Western Cape, South Africa (Mikami, Tsujimura, Sato, Narasada, Shigeta, Kato, Hata 
& Hitomi, 2015). In comparison to Camelia sinensis teas (black and green tea), it is a caffeine-
free herbal infusion/tisane, low in tannin levels (Joubert & de Beer, 2012; Ku, Kwak, Kim & 
Bae, 2014). Rooibos is known for its flavonoid composition, particularly the unique flavonoids, 
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aspalathin and aspalalinin. Aspalathin is a C-C linked dihydrochalcone glucoside and 
aspalalinin, a cyclic dihydrochalcone. Nothofagin, a 3-dehydroxydihydrochalcone glucoside is 
amongst the flavonoids isolated from rooibos, with vitexin and iso-vitexin as its flavone 
derivatives. Other flavonoids detected in rooibos include, orientin and iso-orientin. The list of 
flavonols detected in rooibos include luteolin, rutin, isoquercitrin, quercetin, and catechin (Ku 
et al., 2014; Snijman, Swanevelder, Joubert, Green & Gelderblom, 2007). 
After harvest, rooibos is processed into two different herbal infusions, fermented and 
unfermented as shown in Fig 1.10 (Olawale et al., 2015). The stems and leaves are bruised and 
fermented yielding traditional rooibos, red in colour. The latter product is unfermented; thus, 
its colour is preserved and is classified as green rooibos (Olawale et al., 2015). During the 
processing of green rooibos, the oxidation step is kept to a minimum. The rooibos shoots are 
immediately dried at low temperatures and air humidity before being shredded to a certain 
moisture content (De Beer and Joubert, 2002; Krafczyk and Glomb, 2008). 
A B  
Figure 1.8 Fermented (A) and unfermented rooibos (B).  
Thereafter, the shoots are further dried in controlled temperatures until the desired moisture is 
reached (Van Der Merwe, De Beer, Joubert & Gelderblom, 2015). The traditional rooibos has 
a sweet aromatic profile and occasionally a caramel note, whilst green rooibos has a hay-like 
and grassy aroma (Schulz, Joubert & Schütze, 2003). 
The fermentation process reduces the polyphenolic content of rooibos and consequently 
resulting in a major decrease in aspalathin levels, the major bioactive compound in rooibos 
(Villaño, Pecorari, Testa, Raguzzini, Stalmach, Crozier, Tubili & Serafini, 2010). As a result, 
high levels of polyphenols, flavonoids and non-flavonoids have been quantified in unfermented 
green rooibos relative to the fermented red rooibos (Villaño et al., 2010). Studies have proven 
that the aspalathin content in unfermented green rooibos is 50X higher compared to the 
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fermented rooibos (Bramati, Minoggio, Gardana, Simonetti, Mauri & Pietta, 2002). The 
process of fermentation also affects the antioxidant activity as a result of low total polyphenolic 
content (Awoniyi, Aboua, Marnewick & Brooks, 2012). 
The unfermented rooibos is the most commonly used product to generate aspalathin-rich 
extracts as opposed to the fermented rooibos, as a result of the high phenolic content. To 
elaborate, powered extracts, such as an aspalathin-enriched green rooibos extract (GRE) and 
the pure aspalathin have been produced from the unfermented green rooibos and have been 
used in extensively in experimental studies to study their health benefits  (Van Der Merwe, De 
Beer, Joubert & Gelderblom, 2015).  
Unfermented rooibos has been of interest in investigating its beneficial health effects in obesity 
related cardiovascular risk factors and diabetic related conditions. The combination of rooibos 
polyphenols ensures effective dose delivery as opposed to one isolated antioxidant 
(Marnewick, Rautenbach, Venter, Neethling, Blackhurst, Wolmarans & Macharia, 2011). 
1.17 Health Promoting Medicinal Effects Rooibos  
Marnewick and colleagues (2011), documented an inverse correlation between high flavonoid 
consumption and cardiovascular risk (heart attack, stroke). A daily consumption of 6 cups of 
rooibos in 6 weeks yielded a maximum health benefit (Marnewick et al., 2011). This was 
mainly attributed to its polyphenolic constituents (Pandey et al, 2009).  
Rooibos has been proven to possess anti-oxidant properties (Van Der Merwe et al., 2015), anti-
hypertensive (Persson, Josefsson & Andersson, 2006; Persson, Persson, Hägg & Andersson, 
2010), anti-mutagenic, anti-inflammatory (Baba, Ohtsuka, Haruna, Lee, Nagata, Maeda, 
Yamashiro & Shimizu, 2009) and anti-diabetic effects (Muller, Joubert, De Beer, Sanderson, 
Malherbe, Fey & Louw, 2012; Son, Minakawa, Miura & Yagasaki, 2013). Studies have further 
shown that it inhibits lipid peroxidation (Cullere, Hoffman & Zotte, 2013) and lowers blood 
glucose levels and has cancer modulating effects (Kawano, Nakamura, Hata, Minakawa, Miura 
& Yagasaki, 2009; Mikami, Tsujimura, Sato, Narasada, Shigeta, Kato, Hata & Hitomi, 2015; 
Muller et al., 2012; Son et al., 2013). GRE has also been shown to possess protective effects 
against DNA damage caused by free radicals, thus inhibiting the oxidation of cholesterol which 
results in clogged arteries, heart attack and stroke and preventing development of cancer (anti-
cancer effects) (Gelderblom, Joubert, Gamieldien, Sissing, Malherbe & Maritz, 2017).  
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The health benefits of aspalathin are equivalent to its bioavailability or how it is metabolised 
by the body. Therefore, absorption of this flavonoid has been quantified in humans in order to 
evaluate its biological importance. The plant flavonoids have radical scavenging capabilities 
(Snijman, Swanevelder, Joubert, Green & Gelderblom, 2007). Chronic high consumption of 
plant phytochemicals results in improved redox status due to their anti-oxidant activity (Chu et 
al., 2014).  
In a study done by Chen (2013), aspalathin exhibited potent protective effects against oxidative 
stress in Caenorhabditis elegans subjected to high glucose concentration compared to 
fermented rooibos. Furthermore, aspalathin attenuates H2O2 the anions and other free radical 
species (Chen, Sudji, Wang, Joubert, Van Wyk & Wink, 2013)  
Oxidative stress has been show to impair insulin action and glucose uptake in myotubes is 
reduced (Kawano et al., 2009). High levels of ROS trigger insulin resistance and suppression 
of oxidative stress has been shown to improve insulin sensitivity and increase glucose 
homeostasis (Houstis et al., 2006).  
A study done by Kamakura (2015) showed intracellular ROS scavenging ability of GRE by 
reducing the advanced glycation end products (AGEs)-induced ROS levels in cultured RIN-5F 
pancreatic cells thus protecting them from oxidative stress (Kamakura, Son, de Beer, Joubert, 
Miura & Yagasaki, 2015).  
In vitro studies have shown the effects of GRE and aspalathin to enhance glucose uptake in 
cultured muscles cells (L6 myotubes) and cultured RIN-5F pancreatic beta cells in the absence 
of insulin (Kawano et al., 2009; Kamakura et al., 2015). It also promotes the uptake of glucose 
by stimulating the translocation of GLUT4 into the plasma membrane by inducing 
phosphorylation of AMPK and PKB (Kamakura et al, 2015; Son et al., 2013). Furthermore, 
studies done in vivo using a type 2 diabetic model KK-Ay and db/db mice have shown the 
suppressive effects of GRE and aspalathin have on the increases in fasting blood glucose levels, 
thus reducing glucose intolerance (Kamakura et al., 2015; Kawano et al., 2009).  
Aspalathin has also been proven to decrease blood glucose levels in streptozotocin (STZ)-
induced diabetic rats (Muller et al., 2012) and increases the production of insulin by the 
pancreatic beta cells (Kawano et al., 2009). According to a study done by Kamakura and 
colleagues (2015), the fermented rooibos extract was not effective in reducing the plasma 
glucose levels, due to its low aspalathin content.  
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1.18 Conclusion  
Obesity is a modifiable cardiovascular risk factor, strongly associated with the development of 
insulin resistance, T2D and hypertension. It is characterised by endothelial dysfunction (ED) 
via a reduction in nitric oxide bioavailability and an increase in oxidative stress and 
inflammation, disrupting vascular homeostasis. Individuals with the comorbidities induced by 
obesity are at a high risk of developing CVDs, such as atherosclerosis, stroke and myocardial 
infarction. CVDs are the major contributors to mortality. The emerging CVD related mortality 
can be reversed by effectively controlling CVD behavioural risk factors, such as obesity and 
lack of physical activity. Additionally, adaptions to lifestyle changes reverse the early stages 
before manifesting to irreversible chronic damage. Plant polyphenols have been shown to have 
ameliorative effects against the obesity-induced CVD risk factors, especially polyphenols 
derived from the rooibos plant. Rooibos (Aspalathus linearis), is rich in polyphenols such as 
aspalathin, and is well-known for its numerous health promoting properties. These include 
antidiabetic, anti-inflammatory, antioxidant, anti-obesity and cardiovascular benefits. 
Therefore, Rooibos may have potential in order to counteract the deleterious effects of obesity 
on cardiovascular health.  
1.19 Motivation of the study and Origin of the GRT Extract 
CVD are the leading cause of death worldwide, accountable for 17.7 million deaths annually 
(World Health Organization, 2011). Obesity is a major risk factor for the development of CVD 
and is associated with the development of insulin resistance, hypertension, increased leptin 
levels, impaired glucose and lipid homeostasis (Kim, Després & Koh, 2016; Lteif, Han & 
Mather, 2005; Rader, 2007; Xia & Li, 2017). In South Africa, obesity is more prevalent in 
women than in men (Baleta & Mitchell, 2014). Obesity is also characterised by ED via a 
reduction in NO bioavailability, and an increase in oxidative stress and inflammation, which 
disrupts vascular homeostasis (Prieto, Contreras & Sánchez, 2014). 
Rooibos (Aspalathus linearis), particularly the unfermented green rooibos, is rich in 
polyphenols such as aspalathin and nothofagin and its health promoting properties include 
antidiabetic, anti-hypertensive, anti-inflammatory, antioxidant and anti-obesity effects. These 
health benefits are attributed to the flavonoid content, especially aspalathin.  
AfriplexTM GRT (GRT) extract, an aspalathin-rich Aspalathus linearis extract, used in this 
study is a spray-dried powder produced from unfermented green rooibos. The GRT extract was 
Stellenbosch University  https://scholar.sun.ac.za
29 
 
prepared and standardized by the Afriplex (Pty) Ltd pharmaceutical company in Paarl, South 
Africa. To date, there is no information available on the effects of GRT extract on obesity-
induced cardiovascular risk factors, such as insulin resistance, hypertension, impaired glucose 
tolerance, vascular function and oxidative stress. Further research into the cardiovascular 
benefits of the GRT extract were thus deemed necessary in order to elucidate its potential for 
use in the amelioration of obesity-related cardiovascular effects.  
1.20 Research Question  
Does the GRT extract alleviate elevated blood pressure, vascular dysfunction and oxidative 
stress in diet-induced obese Wistar rats? 
1.21 Research Aim  
To investigate the ameliorative effects of the GRT extract and the mechanisms involved, on 
elevated blood pressure, vascular dysfunction, and oxidative stress in diet-induced obese 
Wistar rats.  
1.22 Research Objectives  
I. To establish an in vivo Wistar rat model receiving treatment for 16 weeks with a high-
fat-diet to induce hypertension and obesity.  
II. To determine vascular reactivity in diet-induced obese and age matched Control Wistar 
rats using thoracic aorta with perivascular adipose tissue (PVAT). 
III. To determine antioxidant status by measuring the activities of the primary antioxidant 
enzymes, and determine oxidative stress by measuring lipid peroxidation in diet-
induced obese and age matched control Wistar rats. 
IV. To determine cardiovascular risk by measuring blood pressure, glucose tolerance in the 
diet-induced obese and age matched Control Wistar rats. 
V. To determine the ameliorative effects of the GRT extract on vascular reactivity, 
antioxidant status, and cardiovascular risk factors in diet-induced obese and age 
matched Control Wistar rats.  
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Chapter 2. Materials and Methods 
2.1 Materials  
Abcam (Pty) Ltd (Cambridge, USA):  Rat Leptin ELISA Kit (ab100773) 
AEC Amersham (Buckinghamshire, United Kingdom (UK)): Horseradish peroxidise-linked 
Anti-Rabbit Immunoglobulin Gene (IgG; Secondary Antibody) and Enhanced 
Chemiluminescence (ECL) Detection Reagent 
Bayer (Pty) Ltd. (Isando, Gauteng, RSA): Eutha-naze (Sodium pentobarbital; C11H17N2NaO3) 
Bio-Rad Inc. (Hercules, California, USA): CriteronTM TGX (Tris Glycine eXtended) stain-
FreeTM precast gels 
Boehriger Mannheim, Cat.127744: Glutathione (GSH; C10H17N3O6S, Cat. 127744) 
Cell Signaling Technologies (Beverly, Massachusetts, USA): Antibodies: Total- and 
Phosphorylated AMPK, Total- and Phosphorylated PKB/AKT, Total- and Phosphorylated 
eNOS 
Cipla MedPro (Pty) Ltd. (Bellville, Western Cape, RSA): GlucoPlus™ (Conventional 
glucose meter Classical Academy (Colorado Springs, US): Trichloroacetic acid (TCA; 
C2HCl3O2) 
Dunedin, New Zealand: LabChart 7 Software 
Fluka Chemie, Switzerland: Butylated hydroxytoluene (BHT) 
Greiner Bio-One Inc. (Monroe, North Carolina, USA): Cryo Vials 
Merck (Pty) Ltd. (Darmstadt, Germany): Sodium Chloride (NaCl), Formaldehyde (CH2O), 
Ethanol (C2H6O). Acrylamide (C3H5NO) and Enzyme-linked Immunosorbent Assay (ELISA) 
kit For Rat/Mouse Insulin. Tris (hydroxylmethyl aminomethane), Methanol (CH4O) and 
Polyvinylidene Difluoride (PVDF) Membrane (Immobilon™-P) 
San Diego, CA, USA: GraphPad Prism® 6 software 
Scientific Group (Pty) Ltd. (Milnerton, Western Cape, RSA): Blood Collection Tubes (SGVac 
Tubes) and Storage Eppendorf 
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Sigma (St. Louis, MO, USA): Phenylephrine, Acetylcholine, Bicinchoninic Acid (BCA) 
Protein Assay Kit, Bovine Serum Albumin (BSA), 2-Thiobarbituric acid (TBA; C4H4N2O2S), 
Phenylmethylsulfonyl Flouride (PMSF; C7H7FO2S), Ethylene-
bis(oxyethylenenitrilo)tetraacetic acid (EGTA; C14H24N2O10), Ethylenediaminetetraacetic 
Acid (EDTA; C10H16N2O8), β-glycerophosphate (C3H7Na2O6P), Sodium Orthovanadate 
(Na3VO4), Sodium Dodecyl Sulfate (SDS; C12H25NaO4S), Triton® X-100 (C18H28O5), 
Mercaptoethanol (C2H6OS), Ponceau Red (C18H14N2Na2O7S2), Ammonium Persulfate (APS; 
H8N2O8S2), Commassie Brilliant Blue (C37H34N2Na2O9S3), Aprotinin (C284H432N84O79S7), 
Leupeptin (C20H38N6O4), Polyethylene Glycol Sorbitan Monolaurate (Tween® 20; 
C58H114O26), 1,2-Bis(dimethylamino) ethane (TEMED),  Bromophenol blue (C19H10Br4O5S), 
Captopril, 6-hydroxydopamine (6-OHD; C8H11NO3: Catalogue number (Cat) H8523), 
Potassium dihydrogen phosphate (KH2PO4), Perchloric Acid (HCLO4), 
Diethylenetriaminepentaacetic Acid (DETAPAC; [(HOOCCH2)2NCH2CH2]2NCH2COOH; 
Cat D6518), Triton X-100 (C18H28O5), Hydrogen Peroxide (H2O2), Glutathione Reductase, 
Cat. G3664) Nicotinamide adenine dinucleotide phosphate (NADPH; C21H29N7O17P3, Cat. 
N1630) Sodium Bicarbonate (NaHCO3), Sodium Hydroxide (NaOH), tert-butyly 
Hydroperoxide, Sodium Azide (NaN3 Cat. B2633), Monopotassium Phosphate (KH2PO4), 
Dipotassium Phosphate (K2HPO4), Sodium Phosphate (Na3PO4), 2,2,2-Trichloroethanol 
(C2H3Cl3O),  Secondary SignalBoost
TM Immunoreaction Enhancer For Secondary Signal 
Enhancement, Hamilton syringe, BRAND® standard disposable PMMA (semi-micro) 
cuvettes, TBS (Tris-buffered saline),   
Thermo Scientific (Lithuania, European Union): Molecular Marker For Western Blot 
(PageRuler Prestained Protein Ladder) 
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2.2 Methods 
2.3 Animals and Diets 
Ethical clearance for this study was obtained from the Stellenbosch University Animal Ethics 
Committee (Ethical Number: SU-ACUM15-00102). The study was conducted according to 
“The Revised South African National Standard for the animal care and use for Scientific 
Purposes” (South African Bureau of Standards, SANS 10386, 2008). Adult male Wistar rats 
weighing between 150-210 g and ± 7-8 weeks old were obtained from the Central Animal 
Facility of the Faculty of Medicine and Health Sciences at Stellenbosch University, for the 
purposes of this study. They were housed in stainless steel cages containing 4 rats per cage and 
maintained under a 12-hour day and 12-hour night cycle at 24-25 °C. A total of 48 adult male 
Wistar rats were randomly divided into the high-fat-diet (HFD) and Control groups (8-10 rats/ 
group). The animals were placed on the diet for a total duration of 16 weeks and were on 
treatment for the last 6 weeks of the 16-week diet regime (Fig 2.1). The age-matched control 
group received standard EpolTM rat chow and the diet group received HFD, containing the 
following contents per kg of food; 390 g EpolTM rat chow + 200 millilitre (ml) water, 100 g 
fructose, 10 g cholesterol, 600 g holsum cooking fat, 100 g casein (added to equalize protein 
levels) and two tins of condensed milk (Huisamen, George, Dietrich & Genade, 2013). The 
HFD diet was specifically adapted to induce high blood pressure (Huisamen et al., 2013). Food 
and fluid intake were measured thrice weekly and the animals were weighed once a week. 
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Figure 2.1 Treatment groups (n=8-10/group) for a total duration of 17 weeks.  
2.4 Administration of the treatment  
The GRT extract was kindly supplied by the South African Medical Research Council 
(SAMRC) coupled with the total polyphenolic composition analysis, performed using the High 
performance liquid chromatography (HPLC) method (see Appendix A) (Beelders, 2012). The 
administered GRT extract dose calculation was deduced from available literature on similar 
extracts (Kamakura, Son, de Beer, Joubert, Miura & Yagasaki, 2015; Muller, Joubert, De Beer, 
Sanderson, Malherbe, Fey & Louw, 2012). There is currently no evidence on the exact dosage 
of this specific product. The Captopril dosage was previously used in our laboratory, and used 
as a positive control in the same rat model (Huisamen et al., 2013). A total of 10 rats per group 
in both the HFD and the Control group were treated with 60 mg/kg/day of GRT extract. An 
additional HFD group was included which served as a positive control (n= 8) for blood pressure 
effects, and were treated with Captopril (50 mg/kg/day), an ACE inhibitor and anti-
hypertensive drug (Fig 2.1). The GRT extract and Captopril treatments were prepared in the 
form of strawberry jelly/gelatine blocks and were given to each animal, individually according 
to their body weight (see Appendix B). The untreated groups (without GRT extract or Captopril 
supplementation), were given normal strawberry jelly/gelatine blocks to normalise for the 
additional sugar content present in the jelly/gelatine.  
Adult male 
Wistar rats 
(n=48)
Control
(n=20)
Control 
(n=10)
Control + 
GRT extract 
(n=10)
HFD 
(n=28) 
HFD
(n=10) 
HFD + GRT 
extract 
(n=10)
HFD + 
Captopril 
(n=8)
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2.5  Oral Glucose Tolerance Test (OGTT) 
The OGTT is an experimental procedure that measures the clearance of a glucose load in the 
body (Stern, Williams & Haffner, 2002). This test was done to examine the insulin sensitivity 
of the animals. The OGTT’s were performed in the week before treatment (week 10) and a 
week before sacrifice (week 16) in both the Control and HFD groups. The animals were fasted 
overnight, and had free access to drinking water.  
Fasting blood glucose levels were determined using a GlucoplusTM glucometer after a tail prick 
with a lancet at the tail tip. The animals were anaesthetized by an intraperitoneal injection of 
0.1 µl Eutha-naze (53 mg/kg Sodium Pentobarbital) and baseline (0 min, fasting level) glucose 
levels were taken. The animals were gavaged with 1 g/kg of a sucrose solution (50 %), and the 
disappearance of glucose in the blood was monitored for 2 hours, with blood glucose readings 
taken at 3 min, 5 min, 10 min, 15 min, 20 min, 30 min, 45 min, 60 min, 90 min and 120 min, 
respectively using a glucometer. After the OGTT procedure, the animals were left to recover 
for a week from this metabolic insult, prior to sacrifice. 
 
2.6 Blood Pressure Measurements  
The blood pressure of each animal was measured using a CODA® non-invasive blood pressure 
acquisition system (Kent Scientific), which utilises a volume pressure recording (VPR) tail-
cuff system. The CODA® system measures blood pressure by determining the blood flow in 
the tail (Fig 2.2). Prior to the actual study, the animals were acclimatized to the apparatus (for 
a period of 2 weeks. Blood pressure was then monitored on a weekly basis for 16-weeks, and 
baseline levels determined for 2 weeks prior to treatment. In each session, 10 readings of both 
the systolic and diastolic blood pressure were taken per animal and used to calculate the mean 
systolic and diastolic pressures. 
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Figure 2.2 Measurement of blood pressure in adult male Wistar rats using non-invasive Coda® 
system. Rat on the warming platform with an Occlusion and V-cuff attached to the tail. 
2.7 Sample and Blood Collection  
Animals were weighed prior to sacrifice and euthanised with an overdose of Eutha-naze (160 
mg/kg body weight, intra-peritoneally). To ensure that the animals were in deep-sleep, thus 
showing no responses before opening their chest cavity, a foot-pinch (pedal reflex) and an eye-
reflex test was performed. Following this, non-fasting plasma glucose levels were determined 
via a tail prick, measured using a Glucoplus® glucometer. Non-fasting blood was collected 
from all the animals. It was transferred to vacutainer tubes (SGVac) and allowed to clot at room 
temperature (25°C). Thereafter, the blood was centrifuged at 1200 x g for 10 min at 4 ˚C. The 
serum was collected and aliquoted accordingly and stored at -80 ˚C for further analysis. After 
30 min, the blood was centrifuged at 1200 g for 10 min at 4˚C. The serum was collected and 
aliquoted accordingly and stored at -80˚C for further analysis.  
The liver, kidney, pancreas and the intra-peritoneal (IP) fat, were removed, rinsed, weighed 
and snap-frozen in liquid nitrogen and stored at -80 ˚C for future experimental procedures. For 
the purposes of this study only the liver and IP fat was used for downstream experimental 
procedures. The thoracic aorta was gently excised from the thoracic cavity of the male Wistar 
rats, in presence of the PVAT. The aortic ring was then immediately prepared and used for 
vascular contraction/relaxation experimentation.  
2.8  Vascular contraction/relation studies 
The vascular contraction/relaxation studies were assed in all the groups using the aortic ring 
with PVAT. This was done to determine the endothelial function of these animals. PVAT is 
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the fat surrounding the aortic tissue. In healthy individuals it exerts vasodilatory effects by 
releasing mediators responsible for vasodilation, such as NO. However, in obese individuals, 
the vasodilatory effects of PVAT are diminished as a result of macrophage infiltration and 
oxidative stress, causing compromising the vascular system (Aghamohammadzadeh, 
Greenstein, Yadav, Jeziorska, Hama, Soltani, Pemberton, Ammori, Malik, Soran & Heagerty, 
2013; Aghamohammadzadeh, Unwin, Greenstein & Heagerty, 2016). 
2.8.1 Drug Preparation  
Phenylephrine (Phe) and Acetylcholine (ACh) stocks were prepared in a 0.9 % saline solution. 
Phe stock (0.002 g Phe in 10 ml 0.9 % saline) with a final concentration of 1 mM was prepared 
(Eppendorf tube covered with foil-light sensitive reagent). ACh stock (0.0182 g in 10 ml 0.9 
% saline) with a final concentration of 10 mM was prepared and labelled as stock A. Thereafter, 
stock A was diluted (1 ml of stock A in 9 ml 0.9 % saline) to a final concentration of 1 mM 
stock B.  Finally, stock B was also diluted (1 ml stock B in 9 ml of 0.9 % saline) to a final 
concentration of 100 µM stock C.  
2.8.2 Dissection and Mounting of the Aortic Ring 
The aortic ring was removed by initially grabbing hold of the proximal aortic opening (where 
the heart was cut off), using tweezers and gently cutting horizontally against the spine and the 
aorta. The clotted blood was carefully removed from the lumen of the aorta before cutting it 
into 3-4 mm piece, without removing the PVAT (Fig 2.3). 
 
Figure 2.3 Aortic segments with PVAT, after removing the clotted blood from the lumen. 
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The aortic ring was carefully mounted onto two stainless steel hooks (Fig 2.4) and slowly 
submerged inside the organ bath (AD Instruments, Bella Vista, New South Wales, Australia) 
filled with Krebs-Henseleit buffer (KHB composition in mM: 119 NaCl, 25 NaHCO3, 4.75 
KCl, 1.2 KH2PO4, 0.6 MgSO4.7H2O, 0.6 Na2SO4, 1.25 CaCl2.H2O and 10 glucose) at 37 °C 
optimum temperature. The organ bath was gassed with 95 % oxygen (O2) and 5 % carbon 
dioxide (CO2). The tension was slowly adjusted to 0.2 g ensuring that the aorta did not fall off 
during insertion inside the organ bath. The remaining aortic ring was stored at -80 °C for 
western blot analysis. 
 
Figure 2.4 Aortic ring mounted between two stainless steel hooks submerged in the organ bath filled 
with warm KHB (From Loubser D, MSc thesis, Stellenbosch University, April 2014). 
2.9 Initial Round of Stabilization  
The aortic ring (inside the organ bath) was stabilised for a period of 40 min, and the tension 
was well monitored, changing the buffer after every 10 min. For the first 20 min, the tension 
was slowly adjusted to 0.8 g. Thereafter the tension was gradually increased to 1.5 g and after 
40 min the KHB was changed.  
2.9.1  Initial Round of Contraction/Relaxation  
After 40 min, the organ bath was adjusted to exactly 25 ml, followed by addition of 100 nM 
Phe (2.5 µL of 1 mM stock), whereby maximum contraction was observed prior to adding the 
ACh. ACh (25 µL of stock A) with a concentration of 10 µM was added to the organ bath for 
maximal dilation. To determine whether to proceed with the downstream experiment, the 
percentage relaxation of the aortic ring needed to be at least 70 % indicating an intact, fully 
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functional preparation. The organ bath was rinsed 3 times with pre-warmed KHB, to flush out 
the drugs and refilled up to 25 ml.  
2.9.2 Second Round Stabilisation  
The tension was stabilised at 1.5 g for a period of 30 min and the KHB was changed after very 
10 min during the 30 min period. 
2.9.3 Second Round Cumulative Contraction/Relaxation   
After 30 min, cumulative concentrations of Phe (to induce contraction) and ACh (to induce 
relaxation) were added, respectively, as shown in Table 2.1. After adding the drugs, the data 
was saved and the aortic ring was measured with a ruler and weighed to ensure that the length 
was between 3-4 mm. The organ bath was thoroughly rinsed with boiled distilled water (4 
times) including the string and the steel hooks. The general outline summary of the 
experimental protocol procedure is shown in Fig 2.5, modified from Privett, Kunert, and 
Lombard (2013), vascular reactivity experimental protocol. 
Table 2.1 Cumulative concentrations of Phe and ACh.  
Phenylephrine Acetylcholine 
2.5 µl of stock (100 nM Phe) 7.5 µl of stock C (30 nM ACh) 
5 µl of stock (300 nM Phe) 17.5 µl of stock C (100 nM ACh) 
5 µl of stock (500 nM Phe) 42.5 µl of stock B (1 µM ACh) 
7.5 µl of stock (1 µM Phe) 14.3 µl of stock B (1 µM ACh) 
5 µl of stock (1 µM Phe) 220 µl of stock B (10 µM ACh) 
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Figure 2.5 Graphical illustration summary procedure for the aortic ring studies experimental 
protocol (From Vascular Reactivity: Aortic ring protocol, Laboratory Manual, Stellenbosch 
University, Westcott C, 2017). 
2.10 Western Blot Analysis  
Western blotting was carried out on aortic tissue to determine the expression and activation of 
proteins involved in endothelial health. These proteins included; AMPK, PKB and eNOS.  
2.10.1 Tissue Homogenate Preparation  
The frozen sections of the aortic tissue were pulverized in a liquid nitrogen pre-cooled mortar 
and pestle. The pulverized aortic tissue (40-50 mg) was transferred into a microcentrifuge tube 
filled with 600 µl of lysis buffer (Composition in mM: 20 Tris-HCl (pH 7.5), 1 Ethylene-
bis(oxyethylenenitrilo)tetraacetic acid (EGTA), 1 Ethylenediaminetetraacetic Acid (EDTA), 
150 NaCl, 1 β-glycerophosphate, 2.5 Sodiumpyrophosphate, 1 Na3VO4, 50 nM NaF, 10 μg/μl 
leupeptin, 10 μg/ml Aprotinin, 0.1 % Sodium dodecyl sulfate (SDS), 1% Triton X-100 and 50 
μg/ml Phenylmethylsulfonyl Flouride (PMSF) which was added last. Stainless steel beads (1.6 
mm) were added to the Eppendorf tubes and the samples were homogenised in a Bullet 
blender® 24 (Next Advance, Inc. New York) at speed 8 for 1 min at 4 °C, for a total period of 
3 min with 5 min rest in-between cycles. The samples were allowed to stand on ice for 15 min, 
thereafter they were centrifuged at 15000 rpm for 20 min at 4 °C. The supernatant was then 
transferred into clean Eppendorf tubes.  
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2.10.2 Protein Concentration  
The protein concentration of each sample was determined using the Bradford method 
(Bradford, 1976), immediately after the tissue homogenate preparation step. The supernatant 
of each sample was diluted in two dilution steps: (A) 10 X dilution (10 μl supernatant + 90 μl 
dH20) followed by (B) 5 X dilution (20 μl of (A) + 80 μl dH20) prepared in duplicate. The 10 
X dilution was specifically used to ensure that the unknown samples does not interfere with 
the low pH achieved by the acid in the Bradford reagent, prepared as explained below 
(Bradford, 1976). Bovine serum albumin (BSA) standard stock (5 mg/ml) was diluted in a ratio 
of 1:5 (100 μl BSA stock + 400 μl dH20) and further diluted in duplicate as shown in Table 
2.2. 
Table 2.2 BSA standard dilutions, done in duplicate.  
Stock: [μg/ml] Volume of Stock 
(μl) 
Solvent (dH20) Final volume  
(μl) 
0 0 (Blank) 100  
 
 
100 
 
1.25 5 95 
2.5 10 90 
5 20 80 
10 40 60 
15 60 40 
20 80 20 
The Bradford reagent containing: 500 mg Commassie Brilliant Blue G-250 protein stain, 250 
ml 95 % ethanol and 500 ml phosphoric acid was prepared in a 1:5 dilution (20 ml Bradford 
stock reagent in 80 ml dH2O) and filtered using a double layer of Whatman filter paper.  A 
volume of 900 μl of the diluted Bradford reagent was added to the 100 µl standards and samples 
(B) respectively and allowed to stand for 15 min in order to allow the colour to change from 
red to blue, under acidic conditions. The sample absorbances were then read in the 
spectrophotometer (GENESYS™ 20 Visible Spectrophotometer - Thermo Fisher Scientific) at 
595 nm. The standard curve was generated in MicrosoftTM Excel by plotting the absorbance 
readings (Y-axis) against the standard protein concentration on the X-axis, as shown in Table 
2.2. The sample (lysate) concentrations calculated using the standard curve were further diluted 
with lysis buffer to render equal protein concentrations per volume unit. Thereafter, a 3 X 
Laemmli sample buffer (62.5 mM Tris-HCl (pH 6.8), 4 % SDS, 10 % Glycerol, 0.03 % 
Bromophenol Blue and 5 % β-mercaptoethanol), was added in a 1:2 ratio (Fanglian, 2011). 
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The sample dilution was performed to control and ensure equal protein loading per gel well 
(20 µg/15 µl). The samples were boiled for 5 min and were stored overnight at -80 °C.  
2.10.3 Protein Separation 
The proteins were separated on a Bio-Rad TGX stain-free TM precast gels, with 26 wells (4-
12%) using a Bio-Rad system. The previously stored (-80 °C) samples were boiled again for 5 
min and centrifuged at 5000 rpm for 5 min prior to loading an equal volume of sample in the 
precast gel using a 25 μl Hamilton® syringe (Sigma-Aldrich, St. Louis, MO, USA). A 
molecular marker (5 µl) was loaded in the first lane of the gel to identify the molecular weight 
of the specific proteins of interest and thereafter, the samples were loaded sequentially and 
accordingly into the gel. The running buffer (25 mM Tris, 192 mM glycine and 0.1 % SDS, 
pH 8.3) was added in the outer gel compartment of the running system. The proteins were then 
separated by subjecting the polyacrylamide gel to 100 V, 200 mA for 10 min followed by 200 
V, 200 mA for 50 min. After protein separation, the gels were activated using the Bio-Rad 
ChemiDocTM MP system and the log or record of the exposed PVDF membrane was stored for 
future normalisation purposes of proteins transferred into the membrane (discussed in section 
2.11.4).  
2.10.4 Protein Transfer 
Prior to protein transfer, the Polyvinylidene fluoride (PVDF) membrane was activated by 
wetting it in fresh methanol for 30 sec and then placed in the fridge (4 °C), soaked in transfer 
buffer. The proteins separated by SD-PAGE were transferred onto a PVDF microporous 
membrane using a Bio-Rad Midi-transfer system and transfer buffer (25 mM Tris-HCl, 192 
mM glycine, and 20 % methanol, pH 8.3), for 1 hour at 200 V, 200 mA.  After the transfer, the 
membrane was placed in methanol for 30 seconds and air dried for 15 min. Successful protein 
transfer onto the membrane was visualised utilising the Bio-Rad ChemiDocTM MP system 
(Table 2.3).  
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Table 2.3 Summary of the western blot protein analysis. 
Protein Molecular 
Size 
(kDa) 
Type of 
Gel 
Primary 
Antibody 
dilutions 
Secondary 
Antibody 
dilutions 
Exposure 
Method 
AMPK 62 Precast 
(26 well) 
7.5µl/5ml 
TBS-Tween 
1.25µl/5ml 
TBS-Tween 
Bio-Rad 
ChemiDocTM 
MP System 
PKB 56 Precast 
(26 well) 
7.5µl/5ml 
TBS-Tween 
1.25µl/5ml 
TBS-Tween 
Bio-Rad 
ChemiDocTM 
MP System 
eNOS 140 Precast 
(26 well) 
7.5µl/5ml 
primary 
SignalBoostTM 
7.5µl/5ml 
secondary 
SignalBoostTM 
Bio-Rad 
ChemiDocTM 
MP System 
 
2.10.5  Immunoblot Analysis  
The non-specific sites on all the membranes were blocked with 5 % fat free milk in TBS-Tween 
(Tris-buffered saline and 0.1 % Tween® 20). When the blocking was completed, the 
membranes were thoroughly washed with TBS-Tween for 1-2 hour at 25 °C in the shaker 
(Digisystem laboratory instrument, Inc). Following this, the membranes were incubated 
overnight at 4 °C in a 7.5 µl polyclonal primary antibody solution, diluted in 5ml TBS-Tween 
or in primary SignalBoostTM as indicated in Table 2.3. Thereafter, the membranes were washed 
with TBS-Tween for 30 minutes (3 X 10 min) on a shaker (Digisystem laboratory instrument, 
Inc). All the membranes were again incubated for 1 hour in 1.25 µl HRP-conjugated secondary 
antibody diluted with 5 ml TBS-Tween (Amersham life science, Buckinghamshire, UK), 
except for the eNOS membrane. The secondary antibody for eNOS, was diluted in secondary 
SignalBoostTM Immunoreaction Enhancer for secondary signal enhancement (Sigma-Aldrich, 
St. Louis, MO, USA). The secondary antibody was removed by washing the membranes again 
in TBS-Tween for 30 min (3 x 10 min) on the shaker. The proteins were visualised by 
incubating the membrane with Enhanced chemiluminescence (ECL) detection reagent (2:2 ml 
of black and white ECL) for 5 min. The membranes were exposed in the Bio-Rad ChemiDocTM 
MP system and analysed with Image Lab TM 5.2.1 software (Table 2.3). The obtained values 
from the exposed bands of the blot were normalised towards the full protein that was transferred 
to the PDVF membrane for equal protein loading, as a result Bio-Rad ChemiDocTM MP system 
does not need a loading control.  
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2.10.6 Stripping of membranes  
When the membranes were re-probed with a different specific antibody it was accomplished 
according to the following procedure: Membranes were washed 2 times for 5 min in distilled 
water (dH2O), incubated in 0.2 M sodium hydroxide (NaOH) stripping buffer and washed again 
2 times for 5 min in dH2O. Thereafter, the membranes were incubated in 5% fat free milk in 
TBS-Tween for 2 hours and the procedure described in section 2.10.5 was followed. 
2.11 ELISA Assay 
A commercially available Millipore Rat/Mouse Enzyme-Linked Immunosorbent Assay 
(ELISA) kit was utilised for the quantification of Leptin in the serum collected from non-fasted 
blood of the Control and HFD groups, previously stored at -80 ⁰C described in section 2.7. The 
results were analysed using a four-parameter algorithm (4PL) software ELISA program which 
was used to set up the dose response standard curve (http://www.elisaanalysis.com). This 
ELISA assay was used to determine the expression of leptin levels in the different treatment 
groups, as shown in Fig 2.1. 
2.11.1 Leptin Assay 
A rat leptin antibody coated 96-well plate and other relevant reagents were provided and were 
allowed to equilibrate at room temperature (25 ⁰C) prior to use. A standard stock (50 ng/ml) 
solution was diluted with 1 X assay diluent D and subsequently diluted to concentrations 
ranging from 8,000 pg/ml to 39.92 pg/ml to yield the leptin standard curve (Fig 2.6). A blank 
composed of only the assay diluent D was included. The samples were diluted with 1 X assay 
diluent D to bring them within the linear standard value range. Standards and sample (100 µl) 
were added in duplicate to the appropriate wells and the plate was incubated for 2.5 hours at 
room temperature with gentle shaking.   
After incubation, the plate was washed 4 times by filling the wells with 300 µl of 1 X wash 
buffer solution. Excess wash buffer after the final wash was aspirated and the plate was dried 
thoroughly. 100 µl of biotinylated anti-rat leptin antibody was added to all the wells and the 
plate was incubated for 1 hour at room temperature with gentle shaking. The solution was 
discarded and the wash step was repeated as described above. Following this, 100 µl of 1 X 
HRP-Streptavidin solution was added to all the wells and the plate was incubated for 45 min at 
room temperature in the dark with gentle shaking. The solution was discarded and the plate 
was thoroughly washed. Thereafter, 100 µl of TMB One-Step Substrate Reagent was added to 
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all the wells and the plate was incubated for 30 min at room temperature in the dark with mild 
shaking. The absorbance was read immediately at 450 nm after adding 50 µl of the stop solution 
to all the wells using a FLOUstar® Omega Microplate Reader.  
 
Figure 2.6 Example of a Rat Leptin standard curve with absorbance read at 450 nm (Abcam, 2013). 
2.12 Antioxidant Enzyme Analysis  
2.12.1 Lysate Preparation 
Tissue homogenates were prepared from the previously stored liver tissue at -80 ⁰C, described 
in Section 2.7. Thin sections of the tissue were cut (± 50 mg) and transferred to microcentrifuge 
tubes containing an equal amount of 0.5 mm zirconium beads and 2 volumes of ice cold lysis 
buffer (50 mM Sodium Phosphate, 0.5 % (w/v) Triton X-100, pH 7.5). The samples were 
homogenised in a Bullet blender® 24 (Next Advance, Inc. New York) at speed 8 for 3 min and 
speed 9 for 4 min, with 1 min rest in-between cycles. Thereafter, samples were allowed to stand 
on ice for 30 min and were centrifuged at 15000 rpm for 20 min at 4 ⁰C. Supernatants were 
transferred into Eppendorf tubes and stored at -80 ⁰C for further analysis. 
2.12.2 Determination of Protein Concentration 
Protein concentration of the prepared tissue homogenates was determined by means of a 
Bicinchoninic acid (BCA) protein assay kit. BSA was used as a standard with a concentration 
of 1 mg/ml and was diluted as tabulated in Table 2.4. The samples were diluted with deionised 
water (deiH20) to ensure that the protein concentration was within the linear range of the 
standard protein concentration (200- 1000 µg/ml). A BCA working reagent consisting of 
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Reagent A (BCA solution and Reagent B (copper (II) sulfate pentahydrate 4 % solution) were 
prepared in a 50:1 ratio. Into each well of a 96-well microplate, 25 µl of the standards or 
samples and the blank were assayed in triplicate, followed by 200 µl of the BCA working 
reagent. The plate was placed on an attachment vortex plate and was shaked (Labnet 
International, Inc) for 10 seconds. The plate was incubated for 30 min at 37 ⁰C and the 
absorbance was read at 562 nm in a FLUOstar® Omega Microplate Reader. All calculations 
for the subsequent antioxidant enzyme assays (CAT, SOD, GPx and thiobarbituric acid reactive 
substances: TBARS) were normalised and standardised according to the BCA protein 
concentration. 
Table 2.4 BSA standard preparation.  
Tube Stock (mg/ml) Solvent (deiH20) Final Volume (µl) 
1 (Blank) 0 100 
100 
2 20 80 
3 40 60 
4 60 40 
5 80 20 
2.13 Catalase (CAT)  
Catalase (CAT, Enzyme Commission number (EC) 1.11.1.6 ) is a ubiquitous enzyme that 
catalyses the conversion of two H2O2 molecules into non-harmful compounds, oxygen and two 
water molecules, in mostly aerobic cells (Ellerby & Bredesen, 2000). The liver tissue 
homogenates were diluted to 0.1 µg/ µl protein in assay buffer (50 mM Potassium Phosphate, 
0.5 % Triton X-100, pH 7.0). From the diluted cell lysate, 5 µl was assayed in triplicate in the 
96 well ultraviolet (UV) plate, followed by 170 µl of assay buffer. To initiate the reaction, 50 
µl of H2O2 stock solution was added to all the wells and the absorbance was measured over 5 
min to measure the linear decrease over time, at 240nm in a FLUOstar® Omega Microplate 
Reader. The molar extinction coefficient (43.6 M-1cm-1) adjusted for the well pathlength was 
used to determine catalase activity (µmole H2O2 consumed/min/ µg protein).  
2.14 Superoxide dismutase (SOD) 
Superoxide dismutase (SODs, EC 1.15.1.1) are metalloenzymes that catalyses the dismutation 
of the reactive superoxide radical (O-2) into H2O2 and oxygen, according to the following 
reaction: 2O2
•- + 2H+ + SOD → H2O2 + O2. SODs form part of the cellular antioxidant defence 
system. SOD enzymes have been characterised into three types according to their metal 
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content; Cu/Zn, Mn and Fe. The Cu/Zn and the Mn are localised in the cytosol and 
mitochondria, respectively. The extracellular SOD, is localised in the interstitial spaces of 
tissues and extracellular fluid responsible for the SOD activity in the plasma (Marklund, 1980). 
In this study, only Cu/Zn SOD enzyme was measured, using the cytosolic fraction. SOD 
activity was determined according to the method modified from Ellerby and Bredesen (2000). 
This assay method measures the auto-oxidation of 6-OHD (6-hydroxydopamine) and one unit 
of SOD is defined as the amount of enzyme needed to exhibit 50 % inhibition of auto-oxidation 
of 6-OHD. Total SOD (using the cytosolic fraction) activity was determined using the liver 
tissue homogenates prepared as described in section 2.12.1.  
The tissue homogenates were diluted to 0.1 ug/µl of protein (using the BCA protein 
concentrations). 6-OHD, 1.6 mM, was freshly prepared by adding 50 µl of concentrated (70%) 
perchloric acid (HCLO4) to 10 ml deiH2O. This solution was purged with nitrogen for 15 min 
to remove oxygen and 4 mg of 6-OHD was added to this solution, wrapped in foil and kept on 
ice. The samples (10 µl) and the blank (15 µl SOD assay buffer [50mM Sodium Phosphate, pH 
7.4]), were assayed in triplicate. Following this, 170 µl of 0.1 mM 
Diethylenetriaminepentaacetic acid (DETAPAC), was prepared in SOD assay buffer (1mg in 
25 ml), was added to all the wells. Thereafter, 5 µl of the SOD assay buffer was assayed in all 
the sample wells, excluding the blank well. The reaction was initiated by adding 15 µl of 6-
hydroxydopamine (6-OHD) to all the wells of the 96-well plate. The kinetics of the auto-
oxidation of 6-OHD was monitored at 490 nm for 5 min at 25 ⁰C using the FLUOstar Omega® 
microplate reader. The results were expressed as Units/mg protein. 
2.15 Glutathione Peroxidase (GPx) 
Glutathione Peroxidase (GPx, EC 1.11.1.9) enzyme catalyses the dismutation of lipids and 
hydroperoxides, including H2O2, by reduced glutathione, thus protecting the cells from 
oxidative damage (Ellerby & Bredesen, 2000). The enzymatic activity is measured indirectly 
by a coupled reaction with glutathione reductase (GR, EC 1.8.1.7). Oxidised glutathione 
(GSSG) produced upon reduction of hydroperoxides by GPx is recycled back to its reduced 
state by GR and NADPH, as shown in Fig 2.7. The assay was done according to the method 
modified from Ellerby and Bredesen (2000), in conjunction with that described by (Ajuwon, 
Katengua-Thamahane, Van Rooyen, Oguntibeju & Marnewick, 2013). 
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Figure 2.7 Enzymatic coupled reaction used to determine glutathione peroxidase activity (Caymen 
Chemical, 2016). 
Liver tissue homogenates were prepared as described in section 2.12.1 were diluted using a 2.5 
X dilution (40µl sample: 60µl assay buffer) so that the protein concentration falls between the 
required range (5-10mg/ml). A cocktail solution consisting of; 210 µl assay buffer (50 mM 
Potassium Phosphate, 1 mM EDTA, pH 7.0), 2.5 µl GSH solution (30.7 mg/ ml, in deH2O), 
2.5 µl GR (1.6 mg/ml, diluted in assay buffer), 2.5µl of 0.1M Sodium azide to inhibit catalase 
and lastly and 2.5 µl NADPH (5 mg dissolved in 0.1% NaHCO3) was prepared. Following this, 
5 µl of the sample and blank (Assay buffer: 50 mM Potassium Phosphate, 1 mM EDTA, pH 
7.0) were assayed in triplicate. Thereafter, 215 µl of the cocktail solution was added in all the 
wells. The absorbance of NADPH oxidation in the absence of H2O2 was measured 3 min with 
30 second intervals at 340nm. Thereafter, to initiate the reaction, 25µl of 1.5mM H2O2 (3.4µl 
of 30% stock solution in 20ml assay buffer) was added to the microplate immediately after the 
first absorbance measurement. The hydroperoxide-dependent linear NADPH oxidation was 
recorded for 2-5 min in 30 second intervals at the same wavelength. The GPx activity was 
expressed as µmol NADPH oxidized/min.   
2.16 Thiobarbituric acid reactive substances (TBARS) Assay  
Measurement of TBARS is a widely used assay method for the determination of lipid 
peroxidation in tissue homogenates and serves as an indicator of oxidative stress. MDA is a 
naturally occurring product of lipid peroxidation which forms an adduct with thiobarbituric 
acid (TBA) under high temperatures (90-100 °C) and acidic conditions (Fig 2.8). The TBARS 
assay method calorimetrically measures the MDA-TBA adduct at 530 nm absorbance. The 
assay was performed according to the modified method of Esterbauer and Cheeseman (1990). 
Stellenbosch University  https://scholar.sun.ac.za
48 
 
 
Figure 2.8 Formation of the MDA-TBA adduct under high temperatures and acidic conditions 
(Caymen Chemical, 2014). 
The liver tissue was homogenised in 0.01 mM sodium phosphate buffer (pH 7.5) containing 
1.15 % KCl. The samples were homogenised in a Bullet blender® 24 (Next Advance, NYC, 
USA) at speed 8 for 3 min and speed 9 for 4 min, with 1 min rest in-between cycles. Thereafter, 
the samples were aliquoted and stored at -80 °C. Protein concentration was determined as 
described in section 2.12.2. The MDA standard solution (500 µM) was prepared by diluting 
1.23 µl of the MDA stock solution in 10 ml of deionised water (deiH2O). Following this, the 
MDA standard dilution series was prepared according to Table 2.5. Samples and standards 
(100 µl) were added in glass test tubes followed by 100 µl of 2 % SDS solution and vortexed 
thoroughly. Thereafter, TCA reagent (10 % TCA, BHT [12.5mM BHT/ 10 ml TCA solution]) 
and 2ml TBA (0.67 % w/v) solution were added on the side of each tube and the glass tubes, 
capped with marbles. The tubes were incubated in a water bath at 95 ⁰C for 1 hour. After 
incubation, the glass tubes were cooled to room temperature in an ice bath, for 10 min. 
Following this, the samples were centrifuged at 3000 rpm for 15 min. The supernatant was 
removed and pipetted into a clean microcentrifuge tube, thereafter, 150 µl was plated in 
triplicate in a 96 well microplate. The absorbance was then measured at 530 nm using the 
FLUOstar Omega® microplate reader. The results were normalized using the previously 
determined protein concentrations and expressed in µmole MDA equivalent/mg protein. 
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Table 2.5 MDA standard preparation.  
Tube MDA standard (µl) MDA Diluent  (µl) Final 
Concentration  
(nmol/ml MDA) 
A 0 1000 0 
B 2.5 997.5 0.322 
C 5 995 0.625 
D 10 990 1.25 
E 20 980 2.5 
F 40 960 5 
G 80 920 10 
H 200 800 25 
I 400 600 30 
2.17 Statistical Analysis  
All the results were analysed using GraphPad Prism® 6. Statistical analysis was done using 
one-way or two-way analysis of variance (ANOVA) followed by the Bonferroni post-hoc test 
for comparison within the groups. The results were expressed as the Mean ± Standard Error of 
Mean (SEM). A probability of p < 0.05 was considered significant.  
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Chapter 3. Results 
3.1 Overview  
Male Wistar rats were fed a HFD composed of 390 g standard rat-chow, 200 ml water, 600 g 
holsum cooking fat, 10 g cholesterol, 100 g fructose, 100 g casein and two tins of condensed 
milk for 16-weeks, compared to aged-matched chow-fed Controls. The HFD was designed to 
induce obesity and specifically hypertension. Half of each animal group was treated with GRT 
extract, given in the form of jelly blocks from week 10 till week 16 (60mg/kg/day). An 
additional HFD group, treated with Captopril (50 mg/kg/day), served as a positive control 
against the development of hypertension. Captopril is a known anti-hypertensive drug that 
exerts its function by inhibiting the ACE. Using both animal models (Control and HFD), the 
relationship between GRT extract and insulin resistance/hypertension was investigated. All the 
data was statistically analysed using GraphPad® Prism 6 and data is expressed as mean ± SEM. 
(Fig 3.1). 
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Figure 3.1 Summary of the measurements performed throughout the study.  
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3.2 Baseline Studies: Biometric and Blood Pressure 
Measurements 
Below are the measurements at baseline (over 10 weeks) of the HFD vs Control group before 
treatment with the GRT extract. 
Table 3.1 Mean food and water intake per rat per day together with the mean body weight gain of the 
HFD vs Control group before treatment with the GRT extract. 
 Mean Food Intake Mean Water Intake Mean Body Weight 
CONTROL 17.18 ± 0.272 g 20.48 ± 0.445 ml 246.00 ± 4.404 g 
HFD 20.58 ± 0.429 g**** 13.60 ± 0.229 ml**** 274.10 ± 4.886 g*** 
All data is expressed as mean ± SEM, (**** p < 0.0001 HFD vs Control, *** p < 0.001 HFD 
vs Control), n = 20-28 per group. 
3.2.1 Mean Food and Water Intake  
The food and water intake were measured thrice a week over the 16-week period. The results 
below represent measurements over the 10 week period. The HFD group showed a significant 
increase in food intake when compared to the Control (20.58 ± 0.429 g vs 17.18 ± 0.272; p < 
0.0001). Furthermore, the HFD group were presented with a significant decrease in the mean 
water intake (13.60 ± 0.229 ml vs  20.48 ± 0.447 ml; p < 0.001) relative to the Control group 
(Fig 3.2 and Fig 3.3), respectively.  
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Figure 3.2 Mean food intake of the HFD vs Control animals over 10 weeks, **** p < 0.0001 (n = 20-
28 per group). 
 
Figure 3.3 Mean water intake of the HFD vs Control animals over 10 weeks, **** p < 0.0001 (n = 
20-28 per group). 
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3.2.2 Initial Mean Body Weight  
Body weight was measured once a week over the 16-week treatment period. The HFD group 
showed a significant increase in the mean body weight at baseline (before the onset of GRT 
treatment) when compared to the Control group (274.10 ± 4.886 g vs 246.00 ± 4.404 g; p < 
0.001).  
 
Figure 3.4 Mean body weight of the HFD vs Control animals in week 10, *** p < 0.001 (n = 20-28 
per group).  
3.2.3 Blood Glucose: Oral Glucose Tolerance Test (OGTT) 
In week 10, quantitative blood glucose measurements were obtained in both the Control and 
HFD group after an overnight fasting period. After the baseline (0 min, fasting level) 
measurement, the animals were gavaged with 1g/kg of sucrose solution and the disappearance 
of plasma glucose levels was measured over 2 hrs at 3 min, 5 min, 15 min, 20 min, 25 min, 30 
min, 45 min, 60 min, 90 min and 120 min.  
At baseline, the HFD group showed a significant increase in plasma blood glucose levels when 
compared to the Control (5.56 ± 0.220 mmol/L vs 4.66 ± 0.113 mmol/L; p < 0.01). After the 
oral administration of the 50 % sucrose solution, the HFD group showed a significant increase 
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area under a curve (AUC, Fig 3.5B) analysis, the HFD group was presented with a significantly 
increase in basal glucose levels when compared to the Control group (716 ± 15.4 vs 635 ± 31.2 
AUC arbitrary units, * p < 0.05). 
Table 3.2 OGTT in HFD vs Control animals (n =7 - 8 per group).  
 CONTROL HFD 
Time (min) Glucose levels (mmol/L) 
0 4.66 ± 0.113 5.56 ± 0.220** 
3 4.84 ± 0.341 6.13 ± 0.219** 
5 5.06 ± 0.229 6.59 ± 0.108**** 
10 5.89 ± 0.245 7.31 ± 0.437* 
15 5.51 ± 0.362 7.63 ± 0.359** 
20 6.40 ± 0.229 7.44 ± 0.270* 
25 6.31 ± 0.212 7.04 ± 0.248* 
30 6.41 ± 0.401 6.84 ± 0.179 
45 5.94 ± 0.292 6.16 ± 0.196 
60 5.34 ± 0.361 5.89 ± 0.250 
90 5.16 ± 0.284 5.16 ± 0.150 
120 4.80 ± 0.213 4.963 ± 0.131  
All data is expressed as mean ± SEM, (* p < 0.05, ** p < 0.01, **** p < 0.0001 HFD vs 
Control. 
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Figure 3.5 A) Glucose levels (mmol/L) and B) AUC representation of glucose tolerance in the HFD 
vs Control group. A) Blood glucose levels (mmol/L) of the HFD vs Control animals measured in week 
10. * p < 0.05 HFD vs Control; ** p < 0.01 HFD vs Control; **** p < 0.0001 HFD vs Control), n = 
7 - 8 per group. 
 
 B) AUC representation of the effect of the diet in glucose tolerance of the HFD vs Control group. * p 
< 0.05, HFD vs Control group, n = 7-8 per group.  
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3.3 Blood Pressure  
The results below reflect baseline blood pressure measurements from week 8-9, before 
treatment with the GRT extract. The HFD group showed a significant increase in the mean 
systolic (Fig 3.6), mean diastolic (Fig 3.7) and mean arterial blood pressure (Fig 3.8) when 
compared to the Control group (Table 3.3). The mean arterial pressure was calculated as 
follows:  
Mean Diastolic Blood Pressure + 
1
3
× (Mean Systolic-Mean Diastolic Blood Pressure) 
 
Table 3.3 Mean systolic, diastolic and arterial pressure of the Control vs HFD group. 
Groups Mean Systolic 
Pressure (mmHg) 
Mean Diastolic 
Pressure (mmHg) 
Mean Arterial 
Pressure (mmHg) 
CONTROL 125.00 ± 1.720 84.48 ± 1.171 99.94 ± 1.480 
HFD 139.00± 2.460**** 93.95 ± 1.226**** 111.70 ± 2.240**** 
All data is expressed in mean ± SEM, (**** p < 0.001 HFD vs Control), n = 20-28 per group  
 
Figure 3.6 Mean systolic blood pressure of the HFD vs Control group (**** p < 0.0001), measured 
from week 8-10, (n = 20-28 per group).  
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Figure 3.7  Mean diastolic blood pressure of the HFD vs Control group (**** p < 0.0001), measured 
from week 8-10, (n = 20-28 per group). 
 
Figure 3.8 Mean arterial pressure of the HFD vs Control group (**** p < 0.000), measured from 
week 8-10, (n = 10 per group). 
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3.4 Results During and after the 16-Week Treatment Period 
3.4.1 Biometric Measurements  
The results below reflect biometric measurement (Mean food and water intake, body weight/ 
gain, IP fat weight and fasting blood glucose levels) analysis. All data is expressed as mean ± 
SEM. 
Table 3.4 Summary of the biometric measurements during and after the 16-week treatment period.  
Groups Food 
 Intake (g) 
Water  
Intake (ml) 
Body 
Weight (g) 
IP fat 
weight (g) 
Fasting blood 
glucose levels 
(mmol/L 
CONTROL 17.11 ± 
0.529 
23.38 ± 
0.442 
339.50 ± 
6.870 
7.32 ± 
0.995 
5.23 ± 0.304 
HFD 20.64 ± 
0.631*** 
17.01 ± 
0.647**** 
396.20 ± 
13.660** 
23.79 ± 
3.481*** 
6.23 ± 0.190* 
CONTROL 
+ GRT 
17.45 ± 
0.468 
26.66 ± 
0.859### 
324.30 ± 
7.460 
8.27 ± 
0.596 
4.83 ± 0.128 
HFD + GRT 21.11 ± 
0.622 
14.76 ± 
1.324 
344.50 ± 
11.740@ 
13.90 ± 
1.315@ 
5.69 ± 0.253 
All data is expressed as mean ± SEM, (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 
HFD vs Control; ### p < 0.001 Control + GRT vs Control; @ p < 0.05 HFD + GRT vs HFD).  
3.4.2 Mean Food Intake  
Food intake was monitored 3 times a week over the 16-week period. The HFD animals showed 
a significant increase in food intake when compared to the Control animals (20.64 ± 0.631 g 
vs 17.11 ± 0.529 g; p < 0.001). Treatment with the GRT extract showed no effect on the food 
intake.  
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Figure 3.9 Mean food intake of the HFD vs Control group (GRT treated and untreated), measured 
over 16 weeks. *** p < 0.001, HFD vs Control group. According to a two-way ANOVA, the HFD 
resulted in a significant increase (p < 0.0001) in food intake, n = 10 per group. 
3.4.3 Mean Water Intake  
Water intake was monitored 3 times a week over the 16-week period. The HFD animals showed 
a significant decrease in the water intake when compared to the Control animals (17.01 ± 0.647 
ml vs 23.38 ± 0.442 ml; p < 0.0001). Treatment with the GRT extract in the treated Control 
animals showed a significant increase in the water intake when compared to the untreated 
Control animals (26.66 ± 0.859 ml vs 23.38 ± 0.442 ml; p < 0.01).  
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Figure 3.10 Mean water intake of the HFD vs Control group (GRT treated and untreated), measured 
over 16 weeks. **** p < 0.0001 HFD vs Control group and ** p < 0.01 Control + GRT vs Control 
group. According to a two-way ANOVA, the HFD resulted in a significant decrease in water intake (p 
< 0.0001), n = 10 per group. 
3.4.4 Body Weight  
The results indicate the absolute body weight of the animals measured in week 16. The HFD 
animals showed a significant increase in body weight when compared to the Control animals 
(396.20 ± 13.660g vs 339.50 ± 6.870 g; p < 0.01). Treatment with the GRT extract in the treated 
HFD animals significantly decreased the body weight when compared to the untreated HFD 
group (344.50 ± 11.740 g vs 396.20 ± 13.660 g; p < 0.05). Additionally, GRT treatment did 
not affect the body weight of the Control animals. 
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Figure 3.11 Body weight measured in week 16 of the HFD vs Control group (GRT treated and 
untreated). ** p < 0.01 HFD vs Control group and * p < 0.05, HFD + GRT vs HFD group. 
According to a two-way ANOVA, the HFD significantly increased (p < 0.001) body weight whereas 
the GRT extract resulted in a significant decrease (p < 0.01) in body weight, n = 10 per group. 
3.4.5 Weekly Body Weight Gain  
The graph below depicts the weekly body weight of the animals groups over the 16 week 
period. The HFD animals showed a significant increase in body weight gain when compared 
to the Control animals (55.71 ± 2.657g vs 36.66 ± 3.033g; p < 0.001). The GRT extract resulted 
in less weight gain in the treated HFD animals when compared to the untreated HFD animals 
(29.40 ± 6.781g vs 55.71 ± 2.657g; p < 0.01). Lastly, treatment with the GRT extract did not 
affect the weight of the treated Control animals. 
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Figure 3.12 Weekly body weight measured over the 16-week period. *** p < 0.001, HFD vs Control 
group and ** p < 0.01 HFD + GRT vs HFD group (n = 10 per group). 
3.4.6 IP Fat Weight 
The HFD animals showed a significant increase in the IP fat weight when compared to the 
Control animals (23.79 ± 3.481 g vs 7.32 ± 0.995 g; p < 0.001). HFD animals treated with GRT 
extract were presented with a decreased IP fat weight when compared to the untreated HFD 
animals (13.90 ± 1.315 g vs 23.79 ± 3.481 g; p < 0.05). Additionally, treatment with the GRT 
extract did not affect the IP fat weight of the Control animals. 
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Figure 3.13 IP fat weight of the HFD vs Control group (GRT treated and untreated) collected and 
weighted in week 16. *** p < 0.001, HFD vs Control and * p < 0.05, HFD + GRT vs HFD. 
According to a two-way ANOVA, the HFD resulted to a significant increase (p < 0.001) in IP fat 
weight, whereas the GRT extract resulted in a significant decrease (p < 0.05) in IP fat weight, n = 10 
per group. 
3.4.7 Liver Weight  
The HFD group had significantly increased liver weight when compared to the Control group 
(15.23 ± 0.8027 g vs 10.30 ± 0.3923 g; p < 0.0001). Treatment with the GRT extract in the 
HFD animals significantly decreased the liver weight when compared to the untreated HFD 
group (11.70 ± 0.5409 g vs 15.23 ± 0.8027 g; p < 0.01). Additionally, treatment with GRT 
extract did not affect the liver weight of the Control animals.  
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Figure 3.14 Liver weight of the HFD vs Control (GRT treated and untreated). **** p < 0.0001, HFD 
vs Control and ** p < 0.01, HFD + GRT vs HFD group. According to a two-way ANOVA, the HFD 
resulted to a significant increase (p < 0.001) in liver weight, whereas the GRT extract resulted in a 
significant decrease (p < 0.05) in liver weight, n = 10 per group.  
3.4.8 Blood Glucose: OGTT 
In week 15, the blood glucose levels (Fig 3.15A) of the HFD and Control (GRT treated and 
untreated) were determined as explained in section 3.2.3. According to the area under a curve 
(AUC, Fig 3.15B) analysis, the HFD animals showed a significant increase in the blood 
glucose levels when compared to the Control animals (741.1 ± 16.20 vs 671.5 ± 23.93 AUC 
arbitrary units; p < 0.05). In addition, treatment with GRT extract significantly decreased blood 
glucose levels in the treated HFD animals when compared to the untreated HFD animals (657.2 
± 32.02 vs 741.1 ± 16.20 AUC arbitrary units; p < 0.05). Furthermore, treatment with GRT 
extract did not affect the glucose levels of the treated Control animals, relative to the untreated 
Control animals (555.9 ± 56.45 vs 671.5 ± 23.93 AUC arbitrary units).  
L
iv
e
r
 W
e
ig
h
t 
(g
)
C o n t r o l H F D
0
5
1 0
1 5
2 0
M in u s  G R T  e x t r a c t
P lu s  G R T  e x t r a c t
* * * *
G r o u p s
E f f e c t  o f  D ie t :  p  <  0 .0 0 0 1
* *
E f f e c t  o f  G R T  e x t r a c t :  p  <  0 .0 5
Stellenbosch University  https://scholar.sun.ac.za
66 
 
 
Figure 3.15 A) Glucose tolerance (mmol/L) and B) AUC analysis for the HFD vs Control group 
(GRT treated and untreated).  
 
 B) AUC representation of the effect of diet and GRT extract in glucose tolerance of the HFD vs 
Control (GRT treated and untreated). * p < 0.05, HFD vs Control group; * p < 0.05, HFD + GRT vs 
HFD group, n = 6-8 per group. According to a two-way ANOVA, the HFD resulted in a significant (p 
< 0.05) increase in blood glucose levels in the HFD animals relative to the Control animals. 
Additionally, the GRT extract significantly (p < 0.05) attenuated the increase in glucose levels in both 
groups.  
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3.5 Leptin Assay 
Biochemical ELISA assays were performed using the serum from non-fasted animals collected 
in week 16. The HFD group showed a significant increase in the leptin levels (Fig 3.16) when 
compared to the Control group (5477 ± 791.50 pg/mL vs 2858 ± 210.80 pg/mL; p < 0.05). 
HFD animals treated with the GRT extract presented with significantly decreased leptin levels 
when compared to the untreated HFD group (2431 ± 608.70 pg/mL vs 5477 ± 791.50 pg/mL; 
p < 0.01). Additionally, treatment with GRT extract did not affect the leptin levels of the 
Control animals.  
 
Figure 3.16 Leptin levels of the HFD vs Control group (GRT treated and untreated). * p < 0.05, HFD 
vs Control group and ** p < 0.01, HFD + GRT vs HFD group. According to a two-way ANOVA, the 
GRT had a significant effect (p < 0.001), on the leptin levels, n = 5 per group. 
3.6 Blood Pressure 
The data below reflect the blood pressure measurements over the last 6 weeks of the 16 week 
diet regime. The HFD group showed a significant increase in the mean systolic (Fig 3.17), 
diastolic (Fig 3.18) and arterial pressure (Fig 3.19) when compared to the Control group (Table 
3.6). Treatment with the GRT extract significantly decreased the mean systolic (Fig 3.17) 
diastolic (Fig 3.18) and arterial pressure (Fig 3.19) in the HFD group when compared to the 
Control group (Table 3.5). Additionally, treatment with Captopril in the HFD animals also 
significantly decreased the mean systolic, diastolic and arterial pressure when compared to the 
untreated HFD group. Treatment with the GRT extract did not affect the blood pressure of the 
Control animals.  
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Table 3.5 Mean systolic, diastolic and arterial pressure of the HFD vs Control group, GRT treated 
and untreated (n = 10 per group).  
Groups Mean Systolic 
Pressure (mmHg) 
Mean Diastolic 
Pressure (mmHg) 
Mean Arterial 
Pressure (mmHg) 
CONTROL 122.30 ± 1.317 81.270 ± 1.645 94.94 ± 1.417 
HFD 134.00 ± 1.770 
*** 
91.64 ± 1.477**** 105.80 ± 1.415**** 
CONTROL + GRT 119.90 ± 1.252 79.22 ± 1.428 92.80 ± 1.283 
HFD + GRT 120.60 ± 1.531#### 81.02 ± 1.482#### 94.22 ± 1.431#### 
HFD + CAPTOPRIL 115.40 ± 
1.381@@@@ 
78.96 ± 
0.7391@@@@ 
91.09 ± 
0.8435@@@@ 
All data is expressed as mean ± SEM, (*** p < 0.001; **** p < 0.0001 HFD vs Control, #### p 
< 0.0001 HFD + GRT vs HFD, @@@@ HFD + Captopril vs HFD). 
 
Figure 3.17 Mean systolic blood pressure of the HFD vs Control group (GRT treated and untreated) 
and the HFD animals treated with Captopril. *** p < 0.001, HFD vs Control; **** p < 0.0001, HFD 
+ GRT vs HFD and HFD + Captopril vs HFD. According to a two-way ANOVA, the GRT extract 
resulted in a significant decrease (p < 0.0001) in the systolic pressure, n = 10 per group.  
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Figure 3.18 Mean diastolic blood pressure of the HFD vs Control group (GRT treated and untreated) 
and the HFD animals treated with Captopril. *** p < 0.001, HFD vs Control; **** p < 0.0001, HFD 
+ GRT vs HFD and HFD + Captopril vs HFD. According to a two-way ANOVA, the GRT extract 
resulted in a significant decrease in the diastolic pressure (p < 0.0001), n = 10 per group.  
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Figure 3.19 Mean arterial blood pressure of the HFD vs Control group (GRT treated and untreated) 
and the HFD animals treated with Captopril. *** p < 0.001, HFD vs Control; **** p < 0.0001, HFD 
+ GRT vs HFD and HFD + Captopril vs HFD. According to a two-way ANOVA , the GRT extract 
resulted in a significant decrease in the mean arterial pressure (p < 0.0001), n = 10 per group. 
3.7 Vascular Reactivity 
Endothelial function of all the groups was assessed by means of isometric tension studies using 
a 3-4 mm section of the aortic ring with the perivascular (PVAT) fat intact. The aortic rings 
were exposed to phenylephrine induced cumulative vasocontraction (Fig 3.20) and 
acetylcholine-induced cumulative vasodilation (Fig 3.21).  
3.7.1 Phenylephrine Induced Vascular Cumulative Contraction  
HFD group showed a significant reduction in vascular contractility when compared to the 
Control group (p = 0.0011). Treatment with the GRT extract significantly decreased 
contraction in the HFD group when compared to the untreated HFD group (p =0.0107).  
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Figure 3.20 Cumulative Phenylephrine induced vascular contraction of the HFD vs Control group 
(GRT treated and untreated), including the HFD + Captopril group. * p < 0.001, HFD vs Control 
and # p < 0.05, HFD + GRT vs HFD ( n = 10-12 per group).  
3.7.2 Acetylcholine Induced Vascular Cumulative Relaxation 
Treatment with the GRT extract significantly increased vascular relaxation in the HFD group 
when compared to the untreated HFD group (p = 0.0001). The same effect was observed in the 
HFD Captopril treated group when compared to the untreated HFD group (p = 0.0123).  
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Figure 3.21 Cumulative Acetylcholine induced vascular relaxation of the HFD vs Control group 
(GRT treated and untreated) including the HFD + Captopril group. * p < 0.0001, HFD + GRT vs 
HFD and # p < 0.05, HFD + Captopril vs HFD ( n = 10-12 per group). 
3.8 Western Blot Analysis  
Western blot analysis of all the groups was carried out in the aortic tissue, previously stored at 
-80°C using 26 well pre-cast gels.  The signalling proteins involved in the endothelial health 
by stimulating NO production, analysed in this study were; AMPK (63kDa), PKB (56kDa) and 
eNOS (140kDa). The data below reflects the total (T) expression, phosphorylated (P) protein 
levels and the ratio (phosphorylation over total expression) of each protein. 
3.8.1 Example of How the Western Blots Were Calculated  
The gel gives a clear indication of the proteins separated (Fig 3.22), whereas the membrane 
gives a presentation of the full set of proteins transferred from the gel (Fig 3.23). The blot gives 
a clear presentation of the specific protein probed for, total AMPK in this example (Fig 3.24). 
The bands in the blot were normalised according to the full amount of proteins transferred to 
the membranes, to eliminate the need of a loading Control.  
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3.8.1.1 Example of the Gel 
 
Figure 3.22: A 26-well Pre-Cast gel depicting successful protein separation. 
3.8.1.2 Example of the Membrane  
 
Figure 3.23: Membrane picture depicting successful protein transfer from the 26-well pre-cast gel.  
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3.8.1.3 Example of the Blot 
 
Figure 3.24: Blot depicting bands of the specific protein probed for, total AMPK in this case with a 
size of 63 kDa. 
3.8.2 AMPK 
The HFD group had significantly lower T-AMPK expression (p < 0.0001) and P-AMPK levels 
(p < 0.0001) when compared to the Control group (Fig 3.25 and Fig 3.26), respectively. The 
Captopril increased the P-AMPK levels in the HFD animals treated with Captopril (p < 0.05) 
when compared to the HFD group (Fig 3.26). The GRT extract and Captopril significantly 
increased of the AMPK P:T ratio in the HFD + GRT extract/Captopril treated group (p < 0.05 
and p < 0.0001, respectively) when compared to the HFD group (Fig 3.27).   
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Figure 3.25 T-AMPK expression in the aortic rings of the HFD vs Control group (GRT treated and 
untreated), including the HFD animals treated with Captopril. **** p < 0.0001, HFD vs Control 
group. According to a two-way ANOVA, the HFD had a significant effect (p < 0.0001) on the T-
AMPK expression, n= 5 per group.  
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Figure 3.26 P-AMPK levels in the aortic rings of the HFD vs Control group (GRT treated and 
untreated), including the HFD animals treated with Captopril. **** p < 0.0001, HFD vs Control 
group; * p < 0.05, HFD + Captopril vs HFD + GRT. According to a two-way ANOVA, the HFD had 
a significant effect (p < 0.001), on the P-AMPK levels n= 5 per group. 
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Figure 3.27 AMPK P:T ratio in the aortic rings of the HFD vs Control group (GRT treated and 
untreated), including the HFD animals treated with Captopril. * p < 0.05, HFD + GRT vs HFD; 
**** p < HFD + Captopril vs HFD. According to the two-way ANOVA, the GRT extract had a 
significant effect (p < 0.05) on the P:T AMPK ratio,  n = 5 per group. 
3.8.3 PKB 
The HFD group (p < 0.001) showed a significant decrease in the total PKB expression and 
phosphorylated PKB levels when compared to the Control group (Fig 3.28 and Fig 3.29). The 
Captopril in the HFD + Captopril group (p < 0.001) significantly increased PKB 
phosphorylation when compared to the HFD group (Fig 3.29). No significant differences were 
observed in the PKB P:T ratio in all the groups assessed (Fig 3.30). 
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Figure 3.28 T-PKB expression in the aortic rings of the HFD vs Control group (GRT treated and 
untreated), including the HFD animals treated with Captopril. *** p < 0.001, HFD vs Control, n =5 
per group. According to a two-way ANOVA, the HFD had a significant effect (p < 0.05), on the T-
PKB expression n= 5 per group. 
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Figure 3.29 P-PKB levels in the aortic rings of the HFD vs Control group (GRT treated and 
untreated), including the HFD animals treated with Captopril. ** p < 0.01, HFD vs Control 
group;*** p < 0.001, HFD + Captopril vs HFD group. According to a two-way ANOVA, the HFD 
had a significant effect (p < 0.01), on P-PKB levels n= 5 per group. 
 
Figure 3.30 P:T PKB ratio in the aortic rings of the HFD vs Control group (GRT treated and 
untreated), including the HFD animals treated with Captopril (n = 5 per group). 
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3.8.4 eNOS 
The GRT extract significantly increased the T-eNOS expression in the HFD + GRT treated 
group (p < 0.01) when compared to the HFD group (Fig 3.31). The HFD and HFD + Captopril 
treated groups (p < 0.001 and p < 0.05, respectively) had significantly increased P-eNOS levels 
when compared to the Control and HFD group (Fig 3.32). The HFD and HFD + Captopril 
treated group (p < 0.01 and p < 0.05, respectively) had significantly increased P:T eNOS ratio 
in the Control and the HFD group (Fig 3.33).  
 
Figure 3.31 T-eNOS expression in the aortic rings of the HFD vs Control group (GRT treated and 
untreated), including the HFD animals treated with Captopril. ** p < 0.01, HFD + GRT vs HFD. 
According to a two-way ANOVA, the GRT had a significant effect (p < 0.01) on the T-eNOS 
expression, n= 5 per group. 
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Figure 3.32 P-eNOS expression in the aortic rings of the HFD vs Control group (GRT treated and 
untreated), including the HFD animals treated with Captopril. *** p < 0.001, HFD vs Control group; 
* p < 0.05, HFD + Captopril vs HFD group. According to a two-way ANOVA, the HFD had a 
significant effect (p < 0.001) on the P-eNOS levels, n= 5 per group. 
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Figure 3.33 P: T eNOS ratio in the aortic rings of the HFD vs Control group (GRT treated and 
untreated), including the HFD animals treated with Captopril. *** p < 0.001 HFD vs Control group; 
HFD + Captopril vs HFD group. According to a two-way ANOVA, the HFD had a significant effect 
(p < 0.001) on the P:T eNOS levels, n= 5 per group.  
3.9 Antioxidant status 
The activities of the primary antioxidant enzymes were determined in the liver.  
3.9.1 SOD  
The HFD animals had significantly low SOD activity when compared to the Control animals 
(227.60 ± 5.631 vs 281.90 ± 10.640 Units/mg protein; p < 0.001). The GRT extract 
significantly increased SOD activity in the HFD treated animals when compared to the 
untreated HFD animals (335.60 ± 37.310 vs 227.60 ± 5.631 Units/mg protein; p < 0.01). 
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Figure 3.34 SOD activity in the liver of the HFD vs Control group (GRT treated and untreated). *** 
p < 0.001, HFD vs Control group; ** p < 0.01, HFD + GRT vs HFD group. According to a two-way 
ANOVA, the GRT extract resulted in a significant increase in SOD activity (p < 0.01), n = 10 per 
group. 
3.9.2 CAT 
The HFD animals had significantly low CAT activity when compared to the Control animals 
(63.59 ± 2.801 vs 91.88 ± 6.507 µmole/min/µg; p < 0.001). Treatment with the GRT extract in 
the treated HFD animals significantly increased catalase activity when compared to the 
untreated HFD animals (76.88 ± 3.900 vs 63.59 ± 2.801 µmole/min/µg; p < 0.05). 
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Figure 3.35 Catalase activity in the liver of the HFD vs Control group (GRT treated and untreated). 
*** p < 0.001, HFD vs Control group;* p < 0.05, HFD + GRT vs HFD group. According to a two-
way ANOVA, the HFD significantly decreased (p < 0.0001) catalase activity, whereas the GRT 
extract significantly increased (p < 0.05) catalase activity, n = 10 per group. 
3.9.3 GPx 
The HFD animals had significantly lower GPx activity relative to the Control animals 
(0.003563 ± 0.000889 vs 0.01848 ± 0.001635 µmole/min); p < 0.0001. The GRT extract in the 
treated Control animals significantly increased the GPx activity when compared to the 
untreated Control animals (0.03535 ± 0.006116 vs 0.01848 ± 0.001635 µmole/min; p < 0.05).  
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Figure 3.36 GPx activity in the liver of the HFD vs Control group (GRT treated and untreated). **** 
p < 0.0001, HFD vs Control group,* p < 0.05, Control + GRT vs Control group, n = 10 per group. 
According to a two-way ANOVA, the HFD resulted in a significant decrease (p < 0.05) in GPx 
activity, whereas the GRT extract resulted in a significant increase in GPx activity,(p < 0.05), n = 10 
per group. 
3.9.4 TBARS 
The HFD animals had significantly increased MDA levels when compared to the Control 
animals (5.12 ± 0.347 vs 3.60 ± 0.276 µmol/mg protein; p < 0.01). Treatment with GRT extract 
in the treated Control significantly decreased the MDA levels when compared to the untreated 
Control group (2.51 ± 0.226 vs 3.60 ± 0.276 µmol/mg protein; p < 0.01). Furthermore, 
supplementation with GRT extract in the HFD animals significantly decreased MDA levels, 
relative to the untreated HFD animals (3.10 ± 0.2841 vs 5.12 ± 0.347 µmol/mg protein; p < 
0.01). 
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Figure 3.37 TBARS levels in the liver of the HFD vs Control group (GRT treated and untreated. ** p 
< 0.01, HFD vs Control group; ** p < 0.01, HFD + GRT vs HFD group; ** p < 0.01, Control + 
GRT vs Control group, n = 10 per group. According to a two-way ANOVA, the HFD resulted in a 
significant increase (p < 0.0001) in TBARS levels, whereas the GRT extract resulted in a significant 
decrease (p < 0.001) in TBARS levels, n = 10 per group. 
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Chapter 4. Discussion 
4.1 Biometric Parameters  
4.1.1 Food and Water Intake  
In the present study, the HFD animals showed a significant increase in mean food intake before and 
after treatment with the GRT extract, when compared to the age matched Controls, Fig 3.2 and Fig 
3.9, respectively. Seemingly, the HFD group enjoyed the HFD diet and this may be attributed to the 
moisture and sweetness of the food. These findings correspond with a previous study which showed 
that, excessive consumption of diets rich in sugar (fructose) content is driven by the pleasure in the 
sweet taste and that excess consumption of a sugar-rich diet subsequently results in obesity (Lenoir, 
Serre, Cantin & Ahmed, 2007). The HFD group drank significantly less water in comparison to the 
Control group, before (Fig 3.3) and after treatment with the GRT extract (Fig 3.10). The significantly 
lower water consumption observed in the HFD group, when compared to the Control group may be 
due to the food being moist as opposed to the dry standard rat chow (pellets) given to the Control 
group, which elicits more fluid intake. A study conducted in humans showed that there is an inverse 
correlation between increased water content and energy intake (Kant, Graubard & Atchison, 2009). 
That is, the higher the sugar content, the lower the fluid intake.  
Treatment with the GRT extract had no significant effect on the mean food intake in both groups (Fig 
3.9). However, it the significantly increased mean water intake in the treated Control group (Fig 3.10) 
when compared to the untreated Control. This corresponds with a study that showed an increase in 
the daily fluid intake by rats drinking unfermented rooibos (Canda, Oguntibeju & Marnewick, 2014). 
This could also potentially be as a result of the dry pellets causing the Control animals to drink more 
water as GRT treatment did not increase the mean fluid intake in the HFD animals. 
In summary: HFD animals had a significantly increased mean food intake when compared to the 
Control animals. Additionally, the HFD animals had a lower fluid intake relative to the Control 
animals. The animals fed HFD seemed to have enjoyed the diet as opposed to the standard rat chow 
due to the food being moist, with a pleasurable sweet taste as opposed the standard rat. This may also 
be the reason for the decreased mean fluid intake observed in the HFD animals, relative to the Control 
animals. The GRT extract increased water intake, and may be a result of the dry standard rat chow 
which they ingested compared to the HFD groups.  
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4.1.2 Body Weight/Gain  
The HFD group showed a significantly increased body weight when compared to the Control group, 
before (Fig 3.4) and after treatment with the GRT extract (Fig 3.11). The animals in all the different 
groups assessed, presented a weekly increase in body weight gain (Fig 3.12). Therefore, the diet 
composition used in this study successfully induced obesity in the HFD group. These findings 
correspond with previous studies done in our laboratory that used the same diet (Huisamen, George, 
Dietrich & Genade, 2013; Salie, Huisamen & Lochner, 2014), including that of other investigators 
who used a diet of similar composition in order induce obesity (Srinivasan, Viswanad, Asrat, Kaul & 
Ramarao, 2005). Treatment with the GRT extract significantly reduced body weight in the treated 
HFD group when compared to the untreated HFD group (Fig 3.11). In addition, treatment with GRT 
extract did not affect the body weight of the Control animals. The above findings are also reflected 
in the weekly body weight gain, emphasising the effect of the diets on the body weight gain of the 
animals.  
The anti-obesity properties of the GRT extract, specifically, have not been investigated. However, 
the anti-obesity effects of the individual polyphenolic compounds (aspalathin, rutin) found in the 
GRT extract (see Appendix A) have been investigated (Choi, Park, Choi & Lee, 2006; Sanderson, 
Mazibuko, Joubert, De Beer, Johnson, Pheiffer, Louw & Muller, 2014). These polyphenols may bring 
about the anti-obesity effects by inhibiting adipogenesis (the differentiation of preadipocytes to 
mature adipocytes) and downregulating the mRNA expression of the transcription factors responsible 
for  adipocyte differentiation such as peroxisome proliferator-activated receptor-gamma (γ) (PPAR- 
γ) (Choi et al., 2006). The mechanism behind the reduction in body weight/gain induced by the GRT 
extract observed in the present study, may be correlated with the anti-obesity findings from the 
previous studies mentioned above. Unfermented rooibos and GRE have been shown to have no effect 
on the body weight of the Control animals fed a standard rat chow (Canda, Oguntibeju & Marnewick, 
2014; Van Der Merwe, De Beer, Joubert & Gelderblom, 2015). This corresponds with our findings, 
as the GRT extract did not affect the body weight of the Control animals.  
In summary: Excess consumption of a high-fat, high-sugar diet is a contributing factor to obesity 
(Srinivasan, Viswanad, Asrat, Kaul & Ramarao, 2005) and obesity has been characterised by an 
increase in calorie intake vs low energy expenditure, which may impair health (Ratzan, 2009). Food 
intake is an important parameter to elucidate body weight gain and the increase in body weight/gain 
correlates with the increased mean food intake observed especially in the HFD group, as discussed in 
section 4.1.1.  GRT extract may be a useful therapeutic agent against obesity and the metabolic 
disorders related to obesity.  
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4.1.3 IP Fat Weight  
The IP fat weight was collected and recorded on the day of sacrifice. The HFD group showed a 
significant increase in the IP fat mass, relative to the age matched Controls (Fig 3.13). The GRT 
extract significantly decreased the IP fat weight in the treated HFD group. Additionally, treatment 
with GRT extract did not affect the IP fat weight of the Control animals.  
An increase in IP fat, as a result of fat accumulation in the abdomen is elicited by excess consumption 
of a high-fat, high-sugar diet and sometimes obesity. In previous studies, rodents fed a HFD were 
presented with an increase in adipose tissue relative to Control animals fed a standard diet (Del Bas, 
Crescenti, Arola-Arnal, Oms-Oliu, Arola & Caimari, 2015; Milagro, Campión & Martíez, 2006).  
Continuous consumption of Rooibos extracts have been shown to decrease the size and number of 
adipose tissue. The mechanism behind this finding, according to this study, was as a result of AMPK 
activation and restoration of the cell energy homeostasis (Beltrán-Debón, Rull, Rodríguez-Sanabria, 
Iswaldi, Herranz-López, Aragonès, Camps, Alonso-Villaverde, Menéndez, Micol, Segura-Carretero 
& Joven, 2011). 
In summary: The HFD animals had increased IP fat mass when compared to the Control animals. 
Treatment with GRT extract significantly decreased IP fat weight in the treated HFD animals but did 
not affect the IP fat weight of the Control animals. These findings correlate with the increase in body 
weight and food intake observed in the HFD group as described in section 4.1.2. Dysfunction of the 
adipose tissue due to fat accumulation result in the dysregulation of adipose tissue. It has been shown 
that enlarged adipose tissue elicit impaired glucose tolerance, and insulin resistance in diet-induced 
rat models (D’Alessandro, Selenscig, Illesca, Chicco & Lombardo, 2015; Rader, 2007). A decrease 
in the IP fat weight can reverse the dysregulation in glucose and lipid homeostasis thus improving 
insulin resistance. Therefore, treatment with GRT extract may be a potential agent used against 
adverse metabolic disorders induced by the enlarged adipose tissue, as a result of obesity, in this case.  
4.1.4 Liver Weight  
The HFD group had significantly increased liver weight, when compared to the Controls (Fig 3.14). 
The GRT extract significantly decreased the liver weight in the HFD treated group when compared 
to the untreated HFD group.  
These findings are consistent with a study done by Milagro et al (2006), that showed an increase in 
liver weight in the animals fed a HFD compared to the animals fed a standard diet. In obese subjects, 
the rate of FFA release from the adipose tissue to the liver and the skeletal muscle is increased. As a 
result, the fat accumulation inside the liver might result in the increased liver weight. Obese patients 
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are often characterised by severe liver disease, NAFLD, when compared to the lean patients with 
NALFD. Fatty liver and the persistent increase in aminotransferase is the cause of liver disease. 
Increase in serum alanine transferase activity is furthermore positively associated with visceral 
obesity, insulin resistance, increase leptin and insulin levels (Fabbrini, Sullivan & Klein, 2010; Ruhl 
& Everharty, 2003). Insulin resistance has been proven to be an independent cause for the 
development of NAFLD (Choudhary, Duseja, Kalra, Das, Dhiman & Chawla, 2012; Farrell & Larter, 
2006; Kumar & Mohan, 2017). When the liver is fatty, it becomes insulin resistant. In this state, 
insulin fails to counteract the increase in glucose levels and hyperglycaemia results. The elevated 
glucose in the liver subsequently is released to the systematic circulation, in the plasma. In the liver, 
insulin resistance increases lipolysis in the adipose tissue and FFA uptake is upregulated (Fabbrini et 
al., 2010). 
Lifestyle changes can also reverse the early stages of NAFLD to the irreversible stage of liver fibrosis. 
Unfermented rooibos, GRE and pure aspalathin extract have been shown to have ameliorative effects  
reversing the dysregulation in lipid homeostasis, glucose homeostasis, lipoprotein metabolism and 
insulin resistance (Kamakura, Son, de Beer, Joubert, Miura & Yagasaki, 2015; Mazibuko, Joubert, 
Johnson, Louw, Opoku & Muller, 2015; Muller, Joubert, De Beer, Sanderson, Malherbe, Fey & 
Louw, 2012). That way it is able to counteract or reverse the NAFLD. 
In summary: The increased liver weight observed in the HFD animals may be attributed to the 
increase FFA release from the enlarged adipose tissue and reduced lipolysis inside the liver. Excessive 
accumulation of triglycerides inside the liver is associated with dysregulation in the lipid and glucose 
homeostasis thus resulting in the development of NALFD amongst pathological conditions such as 
insulin resistance, inflammation and dyslipidaemia and T2D. Increasing prevalence of obesity is the 
initial regulator of the development these pathological conditions. Rooibos extracts have been shown 
to have ameliorative effects against the progression of NALFD to irreversible liver damage by 
regulating glucose, lipid homeostasis including insulin resistance. The effect of the GRT extract in 
reducing liver weight therefore supports these findings, however further investigation into the 
mechanism is needed.  
4.1.5 Blood Glucose  
The HFD group had significantly increased glucose levels when compared to the Control group, 
before (Fig 3.5A) and after treatment with the GRT extract (Fig 3.15B). The GRT extract 
significantly decreased glucose levels in the treated HFD group when compared to the untreated HFD 
group (Fig 3.15B). According to our findings, the HFD reduced glucose metabolism in the HFD 
animals and this corresponds with the previous studies that used the same diet (Salie, Huisamen & 
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Lochner, 2014; Srinivasan, Viswanad, Asrat, Kaul & Ramarao, 2005). Previous studies have 
documented that animals fed the HFD have decreased glucose metabolism (Huisamen, George, 
Dietrich & Genade, 2013). Obesity is strongly associated with the a decrease in glucose metabolism, 
increased fasting blood glucose levels and impaired glucose tolerance and these metabolic changes 
were evident in the HFD-fed animals used in this study. Leptin directly affects insulin levels by 
controlling the pancreatic islets. This implies that, when the leptin levels are high, hyperinsulinemia 
results (Kennedy, Askelund, Premkumar, Phillips, Murphy, Windsor & Petrov, 2016; Wozniak, Gee, 
Wachtel & Frezza, 2009). This subsequently results in hyperglycaemia and this is often seen in obese 
people.  
The GRT extract improved glucose metabolism in the HFD fed animals. GRE extract has been shown 
to suppress the increase in plasma glucose levels in an in vivo study (Mikami, Tsujimura, Sato, 
Narasada, Shigeta, Kato, Hata & Hitomi, 2015). Furthermore, the GRE extract and aspalathin have 
been shown to improve glucose uptake and lipid metabolism in vivo (Mazibuko, Joubert, Johnson, 
Louw, Opoku & Muller, 2015). The major active compound, in the GRE extract, aspalathin,  has been 
shown to increase glucose uptake in muscle cells and insulin secretion by the pancreatic-β cells in 
vitro (Kawano, Nakamura, Hata, Minakawa, Miura & Yagasaki, 2009). In the same study, aspalathin 
decreased fasting blood glucose and improved glucose intolerance in the diabetic rat model, 
confirming the effects of aspalathin on glucose homeostasis (Kawano et al., 2009).  
Anti-diabetic effects of GRE, aspalathin and an unfermented rooibos extract in cultured cells and type 
2 diabetic mice have been documented (Kamakura, Son, de Beer, Joubert, Miura & Yagasaki, 2015; 
Muller, Joubert, De Beer, Sanderson, Malherbe, Fey & Louw, 2012). To elaborate, the GRE extract 
enhanced glucose uptake via the phosphorylation of AMPK and PKB signalling proteins which 
resulted in translocation of the insulin-regulated GLUT4 in the plasma membrane (Kamakura et al., 
2015; Muller et al., 2012), Interestingly, in this study, the GRT extract showed no significant effect 
on the phosphorylation of PKB and AMPK (Fig 3.29 and Fig 3.26), respectively. However, according 
to the P:T AMPK ratio, GRT extract increased the AMPK phosphorylation in the treated HFD group 
(Fig 3.27). This could mean that GRT extract may have induced the upregulation of glucose uptake 
in the tissues via the AMPK pathway.  
In summary: Obesity, especially abdominal obesity, is strongly associated with impaired glucose 
metabolism (D’Alessandro, Selenscig, Illesca, Chicco & Lombardo, 2015) and this results in 
hyperglycaemia. The HFD animals were presented with a reduction in glucose metabolism when 
compared to the Control animals. It has been shown that hyperglycaemia and increased plasma FFA 
leads to ROS generation. This, consequently results in oxidative stress, which then impairs insulin 
signalling thus resulting in insulin resistance (D’Alessandro, Selenscig, Illesca, Chicco & Lombardo, 
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2015; Jung & Choi, 2014). The GRT extract however, increased glucose metabolism in the treated 
HFD animals. This could be as a result of the AMPK phosphorylation according to the upregulated 
P:T AMPK levels. 
4.2 Leptin levels  
The HFD group had significantly increased leptin levels when compared to the control group and the 
GRT extract significantly decreased leptin levels in the treated HFD group when compared to the 
untreated HFD group (Fig 3.14).  
Experimental studies done in rats have shown an increase in leptin levels in the obese rat-rodents fed 
a HFD diet when compared to the rats fed a standard diet (Lozano, Van der Werf, Bietiger, Seyfritz, 
Peronet, Pinget, Jeandidier, Maillard, Marchioni, Sigrist & Dal, 2016; Shapiro, Mu, Roncal, Cheng, 
Johnson & Scarpace, 2008). Obesity has been associated with increased leptin levels (Shapiro, Mu, 
Roncal, Cheng, Johnson & Scarpace, 2008) and it has been reported that elevated leptin levels in an 
obese state are due to the obese (ob) gene mutation (adipocyte-specific) that encodes for leptin, 
resulting in leptin resistance (Considine, Sinha, Heiman, Kriauciunas, Stephens, Nyce, Ohannesian, 
Marco, McKee & Bauer, 1996). It has been shown that the insulin-dependent PI3K pathway plays a 
significant role in leptin resistance, as shown by artificial inhibition of the pathway in a mice model 
(Oswal & Yeo, 2010). The PI3K pathway is also involved in energy homeostasis with leptin and 
insulin acting together to elicit this balance (Oswal & Yeo, 2010). 
In obese humans, there appears to be a reduction in leptin transport from the plasma/peripheral tissues 
to the blood brain barrier in obese individuals, low leptin levels in the cerebrospinal fluid, compared 
to the plasma (Caro, Kolaczynski, Nyce, Ohannesian, Opentanova, Goldman, Lynn, Zhang, Sinha & 
Considine, 1996; Considine, Sinha, Heiman, Kriauciunas, Stephens, Nyce, Ohannesian, Marco, 
McKee & Bauer, 1996).  
Increased levels of triglycerides interferes with and impairs the transport of leptin across the blood 
brain barrier (Veyrat-Durebex, Poher, Caillon, Somm, Vallet, Charnay & Rohner-Jeanrenaud, 2013). 
In rodents fed a high-fat and high-fructose diet, the increased triglycerides levels elicited insulin and 
leptin resistance (Veyrat-Durebex et al., 2013).  
Leptin is a hormone that regulates weight loss. Rooibos treatment has been shown to decrease leptin 
levels in differentiating 3T3-L1 adipocytes (Sanderson, Mazibuko, Joubert, De Beer, Johnson, 
Pheiffer, Louw & Muller, 2014). According to these findings, one way that GRT extract could have 
induced less weight gain in the animals is by acting on the hypothalamus improving leptin 
transportation across the blood brain barrier thus reducing the leptin levels in the plasma. Further 
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mechanisms need to be explored for example, the inhibitory effects of the pancreatic lipase by the 
GRT extract in vivo and in vitro.  
In summary: According to our findings, it can be concluded that the HFD-fed animals may have been 
leptin resistant, with the failure to reduce or control hunger which subsequently resulted to increased 
food intake (Wang, Obici, Morgan, Barzilai, Feng & Rossetti, 2001). One effective way of reversing 
the pathophysiological conditions induced by obesity is by losing weight or decreasing the 
consumption of energy dense foods with a diet low in energy. GRT extract has exhibited a therapeutic 
potential to be used as an agent against leptin resistance, although further investigations are needed.  
4.3 Blood Pressure  
The HFD group showed a significant increase in the mean systolic, diastolic and arterial pressure 
when compared to the Control, before (Fig 3.6, Fig 3.7 and Fig 3.8) and after the GRT treatment 
(Fig 3.17, Fig 3.18 and Fig 3.19). According to the above findings, the HFD composition used in 
this study resulted in hypertensive effects as measured in weeks 8-9, before treatment with GRT. 
These findings are consistent with a previous study done in our laboratory (Huisamen, George, 
Dietrich & Genade, 2013).  
Obesity has been strongly associated with the development of hypertension and renal injury via 
various mechanisms, including renal sodium reabsorption, impaired pressure natriuresis, defined as 
the relationship between excretion of sodium and mean arterial pressure, and by eliciting volume 
expansion via the activation of RAAS and sympathetic nervous system (SNS). Additionally, 
increased visceral adiposity results in elevated blood pressure via the physical compression of the 
kidneys, due to accumulation of fat inside and around the kidneys (Hall, Do Carmo, Da Silva, Wang 
& Hall, 2015). 
Another mechanism is via increased leptin levels resulting in the stimulation of the SNS (Machleidt, 
Simon, Krapalis, Hallschmid, Lehnert & Sayk, 2013). Experimental studies performed in rodents and 
humans have shown a correlation between increased leptin levels and the development of 
hypertension-induced obesity (Haynes, Morgan, Walsh, Mark & Sivitz, 1997; Machleidt et al., 2013). 
These experimental studies are in accordance with our findings, such that the HFD animals were 
presented with increased leptin levels (Fig 3.16) and an increase in IP fat mass (Fig 3.13) when 
compared to the Control animals. This could be potentially be another mechanism that elicited high 
blood pressure. An impairment in the vasodilatory response is as result of the reduction in NO 
production, a characteristic of ED and ED is strongly associated with hypertension (Hall, do Carmo, 
da Silva, Juncos, Wang & Hall, 2014; Lobato, Filgueira, Akamine, Tostes, Carvalho & Fortes, 2012). 
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This therefore, could be another potential mechanism behind the elevated blood pressure as observed 
in the HFD animals.   
Furthermore, Ang II plays a major role in mediating hypertension by stimulating sodium reabsorption 
(Noblet, Owen, Goodwill, Sassoon & Tune, 2015). Previous studies performed in diet-induced obese 
animals have shown an attenuated response in increased blood pressure and sodium retention when 
ACE is inhibited (Boustany, 2005). In addition, inhibition of the RAAS system may serve as potential 
therapeutic strategy for hypertension, dyslipidaemia and impaired glucose homeostasis (Putnam, 
Shoemaker, Yiannikouris & Cassis, 2012). However, due to limiting factors, the expression of Ang 
II was not investigated in this study, as this could have been another way of elucidating the mechanism 
behind the raised blood pressure, including the inhibitory effects of GRT extract. 
The GRT extract significantly decreased the mean systolic (Fig 3.17), diastolic (Fig 3.18) and arterial 
pressure (Fig 3.19), however, it did not affect the blood pressure of the Control animals as measured 
in the last 6 weeks of the 16 week diet regime. The HFD presented with pre-hypertensive blood 
pressure however, as measured over the same time period. Previous experimental studies have only 
shown the anti-hypertensive effects of unfermented rooibos in vitro and in vivo (Persson, Josefsson 
& Andersson, 2006; Persson, Persson, Hägg & Andersson, 2010; Persson, 2012). To date, no 
experimental studies have been conducted, investigating the blood pressure lowering effects of the 
Afriplex GRT™ extract, in an obese Wistar rat model. A reduction in leptin levels may be an effective 
strategy to lower blood pressure, by reducing visceral fat. As shown in Fig 3.13 and Fig 3.16, the 
GRT extract significantly decreased the IP fat mass and leptin levels, respectively, in the HFD animals 
treated with GRT extract. This could be one of the mechanisms that potentially contributed to the 
reduction in blood pressure, as observed in the HFD animals treated with the GRT extract. 
Additionally, the GRT extract improved the vasodilation of the treated HFD animals, suggesting an 
increased NO production. Due to time and financial constraints, the effects of the GRT extract in NO 
production in aortic endothelial cell was not investigated, as this could have made further contribution 
in elucidating the mechanism behind these findings.  
In summary: Obesity has been strongly associated with elevated blood pressure and studies performed  
in humans have shown a positive correlation between visceral, renal adiposity and hypertension 
(Chandra, Neeland, Berry, Ayers, Rohatgi, Das, Khera, McGuire, De Lemos & Turer, 2014; 
Chughtai, Morgan, Rocco, Stacey, Brinkley, Ding, Nicklas, Hamilton & Hundley, 2010). The HFD 
animals presented with increased blood pressures when compared to the Control animals. This could 
potentially be as a result of the increased leptin levels, visceral fat, impaired vasodilation and fluid 
retention in the HFD animals. However, the GRT extract showed ameliorative effects on increased 
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leptin levels, visceral fat, and improved vasodilation in the treated HFD animals. This implies that 
the GRT extract may be used a therapeutic agent against increased blood pressure and ED.  
4.4 Vascular Function/Reactivity 
At the end of the 16 week feeding period, the aortic rings of all the different groups were isolated and 
immediately used for isometric tension studies. The aortic rings of the HFD animals showed a 
significantly lower contractile response to the administration of Phe when compared to the Control 
animals (Fig 3.20). The GRT extract decreased contraction in the treated HFD animals and further 
increased the relaxation of the aortic rings isolated from the treated HFD animals in response to the 
administration of ACh relative to the untreated HFD group (Fig 3.21). Additionally, the Captopril 
significantly increased the relaxation of the aortic rings isolated from the treated HFD group in 
response to the administration of ACh relative to the untreated HFD group (Fig 3.21).  
Impaired vasodilation is a result of a reduction in NO production, this consequently leads to ED, a 
risk factor for hypertension. Obesity has been shown as the major contributing factor to the reduction 
in NO production (Bernatova, 2014) and increase in body weight has been shown to be an 
independent risk factor for the development of ED (Naderali, Pickavance, Wilding & Williams, 
2001). This is evident in obese individuals, presented with blunted vasodilatory function (Cardillo, 
Campia, Iantorno & Panza, 2004; Naderali et al., 2001). Impairment in NO production is a result of 
eNOS uncoupling, increased activation of nuclear factor kappa beta (NF-κβ), increased expression of 
endothelium-derived contracting factors (EDCF), such as Ang II and ET-1. eNOS uncoupling occurs 
when eNOS produces superoxide instead of NO. This is a result of decreased antioxidant enzymes, 
especially SOD enzyme (Lobato, Filgueira, Akamine, Tostes, Carvalho & Fortes, 2012), also found 
in the present study.  
In a lean state, PVAT produces active molecules that regulates vascular tone, by releasing 
endothelium derived relaxing factors (EDRF), such as NO and adiponectin (Aghamohammadzadeh, 
Unwin, Greenstein & Heagerty, 2016), however experimental studies performed in obese rodents and 
humans showed that the vasodilatory effects of PVAT are attenuated as a result of dysfunction in 
visceral adipose tissue function (Bussey, Withers, Aldous, Edwards & Heagerty, 2016; Gao, Zeng, 
Teoh, Sharma, Abouzahr, Cybulsky, Lamy, Semelhago & Lee, 2005; Lu, Su, Lee & Gao, 2010; 
Virdis, Duranti, Rossi, Dell’Agnello, Santini, Anselmino, Chiarugi, Taddei & Solini, 2015; Xia, 
Weisenburger, Koch, Burkart, Reifenberg, Förstermann & Li, 2017).  
Dysfunction in the visceral adiposity and PVAT are involved in the imbalance between NO 
production and EDCF by stimulating chronic inflammation. Furthermore, metabolic disorders 
stimulated by adipose dysfunction are strongly associated with ED, such as insulin resistance (Lobato, 
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Filgueira, Akamine, Tostes, Carvalho & Fortes, 2012). Insulin regulates vascular homeostasis by 
stimulating NO production via the PI3K pathway resulting thus promoting an increase in blood flow 
and glucose uptake by the skeletal muscle and also regulates the production of ET-1. In an insulin 
resistant state, NO production via the PI3K pathway is impaired and ET-1 production is enhanced, 
resulting in ED (Pessin & Saltiel, 2000). 
In accordance to the above mechanism, the potential mechanisms behind the impaired vasodilation 
observed in the HFD animals in our study, could be as a result of the loss of the PVAT vasodilatory 
effects due to a reduction in the release of the EDRF such as NO. Although the production of NO was 
not measured in the present study, measuring its production would have contributed in further 
elucidating the mechanism behind the impaired vasodilation. Additionally, other mechanisms may be 
as a result of increased IP fat mass, an indication of visceral adipose dysfunction, insulin resistance, 
hyperleptinemia and oxidative stress. Under normal physiological conditions, leptin induces NO 
production via AMPK and PKB pathway, which in turn phosphorylates eNOS. However, in obesity, 
the leptin-NO mediated vasodilatory function is impaired as a result of chronic hyperlipidaemia, 
which leads to the activation of different mechanisms (Bełtowski, 2012). The HFD animals in this 
study have been presented with decrease in insulin sensitivity, increased leptin levels and a decrease 
in the antioxidant enzymes (discussed in section 4.6).  
The aspalathin-rich rooibos has been shown to possess anti-hypertensive effects by inhibiting ACE 
and enhancing NO production (Persson, Josefsson & Andersson, 2006; Persson, Persson, Hägg & 
Andersson, 2010). This is attributed to its polyphenolic content, especially aspalathin, the major 
active flavonoid compound. According to the previous studies on the effects of rooibos polyphenols 
in improving ED, mechanistic ways by which GRT extract induced vasorelaxation could be via NO 
production and through improving in insulin sensitivity, as insulin plays a role in NO production via 
PI3K pathway. Additionally, by upregulating the expression of the antioxidant enzyme, particularly 
SOD to scavenge O2
•- and by improving the function of vasodilatory function of the PVAT. The 
Captopril, an ACE inhibitor, yielded the expected results, as it is an anti-hypertensive drug that 
inhibits the conversion of Ang I to Ang II (Rizos, 2014). 
In summary: The HFD animals were presented with a low contractile response when compared to the 
Control animals. However, there were no observed vasodilatory effects between the HFD animals vs 
Control animals. The GRT extract improved vasorelaxation in the treated HFD animals relative to 
their respective Controls and reduced vasocontraction in the treated Control animals when compared 
to the untreated Controls group. A variety of disorders induced or stimulated by obesity are the 
resultant cause of the impaired endothelial function in the HFD animals. Therefore, the GRT extract 
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with a high aspalathin content can be used as a therapeutic agent in reversing the CVD risk factors, 
such as ED and hypertension.  
4.5 Western Blot Analysis  
The HFD group were presented with significantly lower T-AMPK expression (Fig 3.25) and P-
AMPK (Fig 3.26) levels when compared to the Control group. The GRT extract significantly 
increased the P:T AMPK ratio (Fig 3.27) in the treated HFD group when compared to the untreated 
HFD group. Furthermore, Captopril significantly increased P-AMPK levels in the treated HFD group 
when compared to the untreated HFD group (Fig 3.26). The HFD group showed significantly lower 
T-PKB expression (Fig 3.28) and P-PKB levels (Fig 3.29) when compared to the Control group. The 
GRT extract had no significant effect on the T-PKB expression and P-PKB levels in the HFD and 
Control animals. However, the Captopril significantly increased the P-PKB levels (Fig 3.29) in the 
treated HFD group, relative to the untreated HFD group. No significant differences were observed in 
the P:T PKB ratio (Fig 3.30). The HFD group showed a significantly increased P-eNOS levels (Fig 
3.32) when compared to the Control group. The GRT extract significantly increased T-eNOS in the 
treated HFD animals when compared to the untreated HFD animals (Fig 3.31). Additionally, the 
Captopril significantly increased P-eNOS in the treated HFD group, relative to the untreated HFD 
group. The P:T eNOS ratio (Fig 3.33) in the HFD group was significantly increased when compared 
to the Control group and was further significantly increased by Captopril in the treated HFD animals, 
when compared to the untreated HFD group.  
AMPK is an insulin-independent signalling protein that is activated in stress conditions, such as low 
glucose and ischemic conditions. When activated it stimulates glucose uptake, fatty acid oxidation 
and switches off fatty acid synthesis, triglycerides and glucose through the gluconeogenesis (Hardie, 
2004, 2008). Furthermore, it also stimulates the production of NO via eNOS phosphorylation 
(Fleming, Schulz, Fichtischerer, Kemp, Fisslthaler & Busse, 2003). AMPK is inhibited by elevated 
glucose levels. It has been observed that AMPK activity in obesity is altered, subsequently resulting 
in increased glucose levels, fatty acid synthesis, triglycerides and impaired NO production.  
The HFD animals in this study were presented with impaired vasodilatory function (discussed in 
section 4.4). This may be as a result of the significantly low AMPK and PKB activity observed in the 
western blot analysis of the aortic rings isolated form HFD animals, relative to the Control animals. 
PKB is an insulin dependent pathway. When activated by insulin, it stimulates the production of NO 
via eNOS phosphorylation (Fleming et al., 2003). The HFD animals in the present study were 
presented with an increase in glucose levels as a result of a decrease in insulin sensitivity. This finding 
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potentially explains the low PKB activation, decreased NO and impaired vasodilation observed in the 
HFD animals in this study.  
Interestingly, eNOS expression, which includes total and phosphorylated eNOS levels in the HFD 
animals was increased. As a result of the impaired vasodilation observed in the HFD animals, one 
would expect a downregulation in the eNOS expression in the HFD animals to further elucidate the 
reason behind the impaired vasodilatory function. However, this may be as a result of eNOS 
uncoupling. In this study, the HFD animals were predisposed to oxidative stress as seen in the liver 
potentially explaining the pathophysiological status in the whole organism, hence the conclusion that 
the HFD animals were predisposed to oxidative stress. The increase in the eNOS expression, 
signifying an increase in NO production, when it is coupled with an increase in O2
•- free radical this 
leads to the production of a highly reactive free radical, peroxynitrite. This is a result of the increase 
in NO production that binds with O2
•- free radical, due to increase ROS generation (Yang, Huang, 
Kaley & Sun, 2009).  
The GRT extract significantly increased the phosphorylation of AMPK according to the upregulation 
of the P:T AMPK ratio and T-eNOS. This implies that the GRT extract might have improved the 
production of NO in the treated HFD group via the AMPK pathway. Treatment with rooibos and 
aspalathin has been shown to activate AMPK in in vivo studies (Johnson, Shabalala, Louw, Kappo & 
Muller, 2017; Sanderson, Mazibuko, Joubert, De Beer, Johnson, Pheiffer, Louw & Muller, 2014). 
However, further investigation needs to be done on the effects of GRT extract on the phosphorylation 
of AMPK, PKB and eNOS, as the effects were not observed in this study. This will further elucidate 
the mechanisms of the GRT extract behind some of the findings observed in this study, such as the 
improvement of insulin sensitivity, vasodilation and reduced blood pressure observed in the treated 
HFD animals.  
The Captopril significantly increased P-AMPK, P:T AMPK, P-PKB and P-eNOS in the treated HFD 
animals, when compared to the untreated HFD animals. These findings are in accordance with the 
blood pressure and vascular reactivity results (discussed in section 4.3 and 4.4, respectively). 
Captopril is a known  anti-hypertensive drug that exhibits vasodilatory effects (Huisamen, George, 
Dietrich & Genade, 2013; Rizos, 2014). According to these findings, it upregulated the production of 
NO by activating the signalling pathways responsible for eNOS phosphorylation.   
In summary: The HFD animals were presented with a significant decrease in the T-AMPK, P-AMPK, 
T-PKB and P-PKB when compared to the Control animals. In addition, the HFD animals had  
increased P-eNOS relative to the Control animals. The GRT extract increased the P:T AMPK and T-
eNOS in the HFD treated animals when compared to the untreated HFD.  
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4.6 Antioxidant Status  
The activity of the endogenous antioxidant enzymes was measured in the liver. CAT, GPx and SOD 
activity was analysed, including determination of lipid peroxidation. Due to time constraints, the 
activity of the above mentioned enzymes in the kidney, pancreas and aortic tissue was not assessed 
as proposed, to further elucidate the mechanisms behind some of the findings observed in this study. 
In the liver, the HFD group showed a significantly low SOD, CAT and GPx activity, respectively 
when compared to the Control group (Fig 3.34, Fig3.35 and Fig 3.36). The GRT extract in the HFD 
treated group, significantly increased SOD and CAT activity when compared to the untreated HFD 
group. Furthermore, the GRT extract did not show a significant effect in the GPx activity in the HFD 
treated group when compared to the untreated HFD group. We speculate that this may be due to the 
large standard error in the HFD treated group which could possibly be attributed to some differences 
observed in these lysates for the assay. The GRT extract also significantly increased the GPx activity 
in the Control treated group when compared to the untreated Control group. According to a two-way 
ANOVA, the diet and the GRT extract showed an overall significant effect in SOD, CAT and GPX 
activity in both diet groups. The HFD group showed a significant increase in the MDA levels when 
compared to the Control group (Fig 3.37), indicating increased lipid peroxidation which is an 
indication of oxidative stress. Furthermore, the GRT extract significantly decreased the MDA levels 
in both the Control and the HFD treated group when compared to their counterparts (Fig 3.37). 
According to a two-way ANOVA, the diet and the GRT extract had an overall significant effect in 
the MDA levels in both groups. According to the above findings, these animals were predisposed to 
oxidative stress as a result of the reduction in these innate antioxidant enzymes (CAT, GPx and SOD). 
This is further confirmed by the increased levels of MDA, signifying the presence of lipid 
peroxidation in the liver of these animals. A number of studies have shown a positive correlation 
between prevalence of obesity and a reduction in the innate antioxidant enzymes, subsequently 
resulting in oxidative stress (Tran, Oliver, Rosa & Galassetti, 2012). SOD enzyme catalyses the 
conversion of O2•- into a less reactive product, H2O2 which is further decomposed into H2O and O2 
by the CAT enzyme, and by GPx in a glutathione coupled reaction. It has been observed that in obese 
people, the innate antioxidant enzyme defence system is altered (Gutierrez-Lopez, Garcia-Sanchez, 
Rincon-Viquez, Lara-Padilla, Sierra-Vargas & Olivares-Corichi, 2012; Nikolaidis, Kyparos, Spanou, 
Paschalis, Theodorou & Vrabas, 2012). CAT, SOD, GPx activity in both obese adults and children 
has been found to be downregulated, coupled with increased MDA levels (Mittal & Kant, 2009; 
Viroonudomphol, Pongpaew, Tungtrongchitr, Phonrat, Supawan, Vudhivai & Schelp, 2000). 
Therefore, there exists a positive correlation between increasing BMI and oxidative stress.  
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The liver is a very dynamic organ responsible for various physiological and biochemical functions to 
ensure metabolic homeostasis. Additionally, it is also highly reactive against xenobiotics and 
therefore also susceptible to toxic effects. As a result, when the biochemical functions are disrupted, 
liver damage may result. Obesity has been rendered the major contributor to liver disease, such as 
NAFLD, primarily as a result of the adipocytokines secreted by the enlarged adipose tissue, triggering 
subsequent pathophysiological conditions, such as hyperglycaemia, hyperlipidaemia, diabetes and 
hypertension (Polimeni, Del Ben, Baratta, Perri, Albanese, Pastori, Violi & Angelico, 2015; Reccia, 
Kumar, Akladios, Virdis, Pai, Habib & Spalding, 2017).  
NAFLD is characterised by mitochondrial dysfunction as a result of ROS overproduction by the 
adipocytes. ROS production is induced by hyperglycaemia and overnutrition which overwhelms the 
mitochondria resulting in insulin resistance. Oxidative stress in the liver results in lipid peroxidation, 
inflammation and consequently the pathogenesis of NAFLD (Koroglu, Canbakan, Atay, Hatemi, 
Tuncer, Dobrucali, Sonsuz, Gultepe & Senturk, 2016). A study done in patients with and without 
insulin resistance, showed patients with insulin resistance had increased MDA levels and presented 
with a reduction in SOD activity (Koroglu et al., 2016). Increased leptin levels also contributes to the 
development of oxidative stress by increasing peroxisomal fatty acid and mitochondrial oxidation 
(Bełtowski, 2012; Ceci, Sabatini, Duranti, Savini, Avigliano & Rossi, 2007). The HFD-fed animals 
in this study presented with increased leptin levels.  
Numerous studies have shown that dietary antioxidant supplementation can improve liver function 
and oxidative balance (Murer, Aeberli, Braegger, Gittermann, Hersberger, Leonard, Taylor, Traber 
& Zimmermann, 2014). Plant polyphenols, including those from rooibos, have been shown to have 
ameliorative effects on the antioxidant status (Canda, Oguntibeju & Marnewick, 2014). Unfermented 
rooibos and aspalthin-enriched rich green rooibos extract, in particular, modulates the MDA levels 
(Cullere, Hoffman & Zotte, 2013; Villaño, Pecorari, Testa, Raguzzini, Stalmach, Crozier, Tubili & 
Serafini, 2010). These products improve the redox antioxidant status by enhancing the activity of 
SOD, GPX and CAT enzymes (Villaño et al., 2010). A study done in a rat model has shown that 
rooibos may ameliorates oxidative stress by preventing inflammation via its anti-oxidative activity 
(Baba, Ohtsuka, Haruna, Lee, Nagata, Maeda, Yamashiro & Shimizu, 2009). This is attributed to its 
polyphenolic components, especially aspalathin and nothofagin.  
Other strategies to reduce oxidative stress include physical activity, weight loss and a well-balanced 
diet, rich in antioxidants (Savini, Catani, Evangelista, Gasperi & Avigliano, 2013). A reduction in 
weight loss has been shown to reduce colorectal inflammation as a result of the increase in pro-
inflammatory markers, such as adiponectin and significantly reducing TNF- α and IL-6 (Savini, 
Catani, Evangelista, Gasperi & Avigliano, 2013). An increase in GPx activity has also been observed 
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after weight loss in obese women (Bougoulia, Triantos & Koliakos, 2006). Therefore, a decrease in 
visceral adipose tissue is another important mechanistic way of combating oxidative stress. It has 
been shown that total antioxidant capacity has an inverse effect on visceral adiposity and the GRT 
extract reduced the IP fat mass, which could potentially contribute to the increase expression of the 
innate antioxidant enzymes (Hermsdorff, Puchau, Volp, Barbosa, Bressan, Zulet & Martínez, 2011; 
Del Rio, Agnoli, Pellegrini, Krogh, Brighenti, Mazzeo, Masala, Bendinelli, Berrino, Sieri, Tumino, 
Rollo, Gallo, Sacerdote, Mattiello, Chiodini & Panico, 2011).   
In summary: Obese individuals are presented with an alteration in the antioxidant defence system, 
thus predisposing them to oxidative stress and chronic inflammation. The HFD animals presented 
with a reduction in the activity of the innate primary antioxidant enzymes, such as SOD, CAT and 
GPx when compared to the Control animals. Moreover, these animals had increased MDA levels 
relative to their counterparts, which indicates oxidative stress. However, the GRT extract increased 
the activity of the SOD, CAT and GPx activity and decreased lipid peroxidation in the HFD treated 
animals when compared to the untreated HFD animals.  
4.7 Summary of the Main Findings  
Obesity, especially visceral obesity is strongly associated with the pathogenesis of CVD risk factors, 
such as, impaired glucose homeostasis, dyslipidaemia, hypertension, oxidative stress and ED. The 
HFD used in this study, successfully induced obesity in the Wistar rat model, as to the proposed 
objectives.  This is supported by an increase in leptin, in body weight, IP fat mass and liver mass. 
Furthermore, the HFD impaired glucose metabolism, induced hypertension, ED and oxidative stress, 
which was validated by an increase in lipid peroxidation and the downregulation of CAT, GPx and 
SOD activity in the liver. The HFD also downregulated the expression of AMPK and PKB. This 
could potentially be the result of the observed decrease in glucose metabolism, impaired vascular 
function, and increased blood pressure. However, the observed phosphorylation of eNOS, impaired 
ED and increased blood pressure may also be associated with oxidative stress.  
Our aim was to investigate the ameliorative effects of the GRT extract, on hypertension, vascular 
dysfunction, and oxidative stress in diet-induced obese Wistar rats. Treatment with the GRT extract 
decreased leptin levels, resulted in less weight gain, decreased IP fat mass, liver mass and increased 
glucose metabolism, observed in the treated HFD animals. It also improved vascular function, 
reduced blood pressure and reversed oxidative stress by upregulating the activity of the innate 
antioxidant enzymes, CAT, GPx and SOD, including lipid peroxidation.  A decrease in leptin levels 
has been associated with a decrease in blood pressure and improved vascular function. This may be 
part of the mechanism by which GRT exerted these effects in this study, and includes the upregulation 
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of AMPK expression, and a decrease in visceral adiposity. However, the exact mechanism needs to 
be further explored.  
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Chapter 5. Conclusion 
5.1 Final Conclusion  
Obesity is strongly associated with impaired glucose homeostasis, increased blood pressure, ED, 
dyslipidaemia and oxidative stress, synergistically increasing cardiovascular risk. Considering the 
study research question: “Does ingestion of GRT extract alleviate hypertension, vascular dysfunction 
and oxidative stress in diet-induced obese Wistar rats?” the present study has successfully addressed 
the research question and met the proposed aim. The mechanisms behind the effects of GRT extract 
were elucidated, however, further investigations need to be done. Therefore, GRT extract may be a 
potential therapeutic agent against obesity-related vascular dysfunction, impaired glucose 
homeostasis, elevated blood pressure, oxidative stress, leptin resistance and weight gain.  
5.2 Study Limitations 
• Major limitations were financial and time constraints as we could not measure some of the 
parameters mentioned under future directions that would have further elucidated the 
mechanisms behind our findings. 
5.3 Future Directions 
• Evaluation of the serum and liver lipid profile, LDL, High density lipoprotein (HDL), very 
low-density lipoprotein (VLDL), total cholesterol, triglycerides.  
• Measurement of pro-inflammatory cytokine (IL-6, TNF-α) and anti-inflammatory cytokines 
(adiponectin release) in the serum.  
• Measurement of homeostatic model assessment (HOMA) index to determine insulin levels in 
the fasted and non-fasted serum, using an insulin ELISA assay kit.  
• Measurement of ET-1 and aldosterone expression in the serum to elucidate the effect of GRT 
extract on decreased blood pressure.  
• Investigate the effects of GRT extract on NO production in cultured endothelial cells, 
including Ang II, to further elucidate the vasodilatory effects observed in the treated HFD 
animals. 
• Determination of the ACE inhibitory effects of the GRT extract.  
• Determination of the primary antioxidant enzymes and the assessment of oxidative stress in 
in the pancreas, kidney and aorta.  
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• Determine the effect of GRT extract on pancreatic lipases and its anti-obesity mechanism.  
• Determine the effect of GRT extract on adipose tissue to elucidate the mechanism behind 
decreased IP fat weight. 
• Determination of the mechanism behind decreased liver weight by performing liver 
histopathology.  
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Appendix A: HPLC Analysis of GRT extract 
Table A.1: HPLC analysis of the GRT extract used in the study (Beelders, 2012). 
[compound] (g compound/ 100 g Soluble Solids) 
Phenylpyruvic acid-2-Oglucoside 
(PPAG) 
0.423265 
Aspalathin 12.78348 
Nothofagin 1.974419 
Isoorientin 1.427281 
Orientin 1.255839 
Ferulic acid nq 
Vitexin 0.338513 
Isovitexin 0.298022 
Quercetin-3- robinobioside 1.040565 
Hyperoside 0.398773 
Rutin 0.496034 
Isoquercitin 0.572251852 
Abbreviations: nq (not quantifiable) 
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Appendix B: Preparation of the strawberry jelly/gelatine 
blocks for the animals 
A. Jelly/gelatine block protocol (Normal Batch-25ml)  
• 4 grams red jelly  
• 4 grams gelatine 
• In 25 ml of BOILED water 
B. GRT extract dose concentration was 60 mg/kg/day, and 50 mg/kg/day for Captopril, 
administered according to body weight.(measured once a week)  
• When adding the drug dosage to the jelly/gelatine mixture the following was 
considered;  
• Determine the average body weight of the rat. 
• For example: If the rat weighed 300g, this was multiplied with the extract dosage 
(e.g. 60 mg/kg/day) and divided by 1000 (to cancel out the kg) then multiplied by 
the total volume required for the week in ml. 
C. Calculated example: 
 
300 𝑔 𝑋 60 𝑚𝑔 /𝑘𝑔
1000
𝑋 25 𝑚l 
The end unit value will be mg per ml.  
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